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Summary
Summary
Hepatitis C virus (HCV) is a recently discovered major human pathogen 
infecting 170 million individuals worldwide. It was the first hepatotropic virus to 
be isolated by molecular biology techniques. Since its discovery in 1989 
considerable progress has been made in the identification of the viral functional 
regions, the interactions between viral products, and viral pathogenesis. However, 
little is known about its replication cycle and the only experimental in vivo HCV 
infection model is limited to the chimpanzee. Thus, the development of a cheap 
and accessible in vitro or in vivo culture system has become a priority.
The work in this thesis explores a variety of different approaches to an in 
vivo culture system using the severely combined immunodeficient (SCID) mouse. 
These animals lack functional T and B cells and will accept xenografts from a 
range of species including humans.
Hepatocyte derived cell lines and primary human hepatocytes (PHHC) 
were transplanted intrasplenically and under the renal capsules after performing a 
partial hepatectomy. The rationale rests on the hypothesis that these cells would 
attain a biologically functional state of differentiation in vivo, increasing their 
sensitivity to HCV infection and acting as targets for HCV replication in an in 
vivo culture system. HCV positive serum was used to infect the cells prior to 
transplantation or 3 days post transplantation. PHHCs were also mixed with anti- 
met antibody and interleukin 6 (IL6) prior to transplantation to increase their 
survivability and proliferation in vivo', silica was administered intraperitoneally to 
deplete host macrophage cells.
All the animals transplanted with hepatocyte derived cell lines developed 
extremely large metastatic tumours which were hemorrhagic, additionally these 
cells were not susceptible to HCV infection, irrespective of the route of infection 
and source of the HCV positive serum. PHHCs failed to engraft irrespective of
14
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treatment and were HCV reverse transcription polymerase chain reaction 
(RTPCR) negative.
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CHAPTER 1
Introduction
Hepatitis C virus (HCV) has been identified as the main cause of more 
than 90% of posttransfusion and sporadic non-A, non-B hepatitis (Alter et al 
1992). It chronically infects about 170 million individuals worldwide (World 
Health Organization 1997), the global prevalence is estimated to average 3%. In 
industrialized countries, HCV accounts for 20% of acute hepatitis cases, 70% of 
chronic hepatitis cases, 40% of end-stage cirrhosis, 60% of hepatocellular 
carcinomas and 30% of liver transplants (EASL International consensus 
conference on hepatitis C, 1999). Disease development is associated with low 
grade, persistent viraemia, with various rates of progression. About 15% of HCV 
infected individuals recover spontaneously and 25% have an asymptomatic illness 
with normal aminotransferases (ALT) and benign histological lesions (EASL 
International Consensus conference on hepatitis C, 1999). But, chronicity is the 
most usual outcome of infection, where patients present with a relapsing, 
remitting disease with recurrent bouts of hepatitis marked by fluctuating ALT 
levels, but normal levels have been observed in one third of cases that are HCV 
RNA positive. 20% of patients will develop liver cirrhosis after 20 years of 
infection (Kiyosawa, 1994). Infection is also linked with most cases of type II and 
type m  cryoglobulinemia, which are B lymphocyte proliferative disorders 
characterized by polyclonal B cell activation and autoantibody production 
(Silvesteri et al, 1996).
16
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1.1 Genetic organization of Hepatitis C Virus (HCV)
The complete sequence of HCV was published in 1989 (Choo et al 1989). 
HCV was identified as a positive strand enveloped RNA virus with a length 
averaging 9.5 kb. Its genome, summarised in figure (1.1), includes two 
untranslated regions at the 3’ and 5 ’ ends, and a large open reading frame that 
encodes for a 3010-3030 amino acid polyprotein. This polyprotein is translated 
and cleaved into structural and non-structural proteins. The structural proteins, at 
the N-terminal region, are the core protein followed by two glycosylated putative 
envelope proteins: E l and E2 (Brechot 1996). The hypervariable region 1 (HVR1) 
is located on the 5 ’ end of the second envelope gene E2 and appears to be the one 
of the main targets of anti-HCV neutralising responses (Farci et al 1994). The 
non-structural domain encodes six proteins: NS2, NS3, NS4A, NS4B, NS5A, and 
NS5B (Brechot 1996). The 5 ’ untranslated region (UTR) is highly conserved 
among HCV isolates and shows secondary structures with several stems and loops 
(Smith et al 1995).
------------------------------------------9500 n t-------------------------------------------------------------- ►
<----------------------------9030-9099 nt-----------------------------------------►
E2 NS4
C El (HVR1) NS2 NS3 NS5A NS5B
5 ’UTR 3’UTR
Figure (1.1) Genetic organisation of HCV (Brechot, 1996 and
Pawlotsky, 1998)
The precise structure and function of the 3 ’ UTR region is unclear, though 
it consists of a short stretch of poly (U) or poly (A) nucleotides and is 
heterogeneous among different isolates (Brechot 1996). Because HCV shares 
structural and functional homologies with flaviviruses and pestiviruses, by
17
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analogy with the replicative strategies of these viruses (Cleaves et al 1981, 
Chambers et al 1990), it is possible that this region might influence viral 
replication and pathogenicity.
The NS3 domain codes for three enzymes: serine proteinase, helicase and 
ATP dependent nucleotide tri-phosphatase. NS2 and the N-terminal sequence of 
the NS3 region also code for a second protease; and a heterodimeric complex is 
formed with NS4A and the NS3, which acts as a cofactor for NS3 proteinase 
activity (Hirowatari, et al 1995, Failla et al 1994). A GDD motif conserved 
among RNA dependent RNA polymerases is contained in the NS5B domain, 
which probably acts as the RNA polymerase (Brechot, 1996). For HCV 
replication to occur, the viral polyprotein will probably be translated from the 
virions’s single stranded RNA by the host ribosomes and the protein required for 
HCV replication cleaved. The resulting RNA dependent RNA polymerase may 
then recognise the 3’ end of the viral genome and allow transcription to proceed 
from the 3’ to the 5’ end. Using this negative strand as a template, positive sense 
genomic RNA can then be transcribed. Negative strand intermediates have been 
detected in HCV infected patients (Saleh et al, 1994, Lohr 1995)
As viral RNA polymerase lacks “proof-reading” activity, replication errors 
made are not corrected. Consequently accumulation of mutations that might 
confer different biological properties (Martell et al, 1992), for example the 
emergence of HVR1 variants could partly explain viral persistence (Pawlotsky, 
1998).
As there is no reliable and sensitive tissue culture system, progress in 
understanding the pathogenicity and life cycle of HCV has been limited. There is 
no consensus on HCV cell tropism; the mechanism of viral entry and the cellular 
receptors have not been identified. However, Piled et al demonstrated binding of 
HCV envelope protein E2 to human CD81, a tetraspanin expressed on various cell 
types including hepatocytes (Piled et al, 1998) suggesting a possible receptor site. 
Further the close association of HCV with VLDL or LDL (very low density or 
low density lipoproteins) could explain its hepatotropisim, as the liver is the main 
site of lipoprotein metabolism (Gurr and Harwood, 1991).
18
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The development of an efficient in vitro culture system and readily 
accessible in vivo infection model has thus become a priority for the assessment 
of antiviral strategies, the development of vaccines and analysis of viral 
replication. Currently, the only successful in vivo model is the chimpanzee 
(Shimizu etal, 1990).
1.2 In vitro culture of HCV
1.2.1 HCV culture in permissive cell-lines
A number of permissive cell-lines have been used in attempts to produce 
HCV culture systems. Two approaches have been used to introduce HCV genome 
to the cells: infection and transfection.
1.2.1 a) Infection of permissive cell-lines
HCV positive serum or plasma was used to infect either lymphocytic cell- 
lines: MOLT4 (Shimizu et al, 1993)), MT2C (Kato et al, 1995; Sugiyama et al 
1997), B cells (Bertolini et al, 1993); or liver derived cell-lines: WRL68 and 
HepG2 (Tagawa et al, 1995), HepG2 and Huh7 (Seipp et al, 1997).
Viral replication in lymphocytic cell-lines was found to be transient. In the 
MT2C cell-line, HCV was detected by reverse transcription polymerase chain 
reaction (RT PCR) up to 30 days post inoculation, which in turn was increased to 
80 days after a reduction in the incubation temperature from 37°C to 32°C 
(Mizutani et al 1995). Conversely, Nakajima et al demonstrated the production of 
infectious HCV for more than one year after infecting the T cell line HPBMa 10-2 
and the B cell line Daudi. This was achieved using an inoculum with HCV virions 
that were determined to be free of antibodies by immuno-precipitation with anti­
human immunoglobulin (Nakajima et al 1996).
Several groups have attempted to infect a number of liver derived cell- 
lines with limited and variable success rates. Seipp et al found that HCV RNA 
was detected in Huh7 cells for up to 10 days with a low HCV RNA copy number 
(around 104 copies). The efficiency of detection was increased slightly after the
19
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addition of polyethelene glycol (PEG) and/  or dimethyl sulfoxide (DMSO). 
However, there was no increase in viral titre in long-term cultures, suggesting 
enhanced HCV attachment to the cells but not infection. Further modification to 
the culture conditions and stimulation of the low-density lipoprotein receptor with 
Lovastatin caused persistence of HCV in cells and supernatant up to 130 days, but 
negative strand viral RNAwas absent (Seipp et al, 1997). Conversely, negative 
strand RNA was detected in infected WRL68 cells for more than two months and 
in the supernatant for up to 62 days (Tagawa et al, 1995).
The detection of HCV negative strand RNA is required to prove 
replication but potential artefacts such as self-priming (Brown et al 1992) and 
mispriming (Willems et al 1993) that were not addressed in earlier publications 
have led to misrepresentation of results. Laskus et al recently demonstrated the 
absence of HCV negative strand RNA in circulating peripheral blood 
mononuclear cells (PBMC); also the sequences identified in serum were identical 
to those found in the PBMCs (Laskus et al 1997). New procedures developed by 
Lanford et al, which rely on the use of either tagged HCV primers or thermostable 
reverse transcriptase to optimise negative-strand detection (Lanford et al 1995), 
should clarify the issue of HCV T cell tropism.
1.2.1 b) Transfection of permissive cell-lines
HCV transfection is an alternative approach for the production of a 
continuously infected cell line. Several investigators have transfected subgenomic 
HCV cDNA either into HepG2 (Harada et al 1995) or Hela cells (Mizuno et al 
1995). Structural and non-structural HCV proteins were produced in different 
expression systems, but the constructs did not permit viral replication.
The transfection of full length HCV RNA has been more rewarding. Yoo 
et al transfected HCV RNA produced from a recombinant cDNA clone into Huh7 
cells. HCV negative-strand RNA was detected in both supernatants and cells, and 
50% of cells were found to be HCV positive by in situ nucleic acid hybridisation. 
The viral yield was low and intermittent in the supernatants, and appeared to 
follow cell division (Yoo et al 1995). Recently, Dash et al developed a more
20
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successful culture system by transfecting HepG2 cells with 6.7, 9.6 or 9.4 kb 
RNA. The viral yield in culture was found to be high, at 108-1010 copies, and 
constant over a period of 60 days. Further, virus-like particles were detected by 
electron microscopy (Dash et al 1997). Considerable scepticism, however, has 
been expressed about various technical aspects of this work including the 
infectivity of HCV clones lacking a 3’ end, the large amount of RNA needed for 
RT-PCR, the number of virus-like particles viewed by electron microscopy and 
the high specificity of their RNA negative strand assay (Fausto, 1997). One of the 
main disadvantages of using liver derived cell-lines is that some of them originate 
from hepatocellular tumours, and thus will vary in their states of differentiation 
(Sigal et al 1992). This in turn may lead to the loss of important hepatocyte 
characteristics that could be crucial for virus attachment, infection and replication. 
For example, the cell-line Hep G2 does not express of the CD 81 receptor 
(personal communication from Dr Arvind Patel at the Institute of Virology, MRC 
Virology Unit, Glasgow 1999), which is known to bind E2. This in turn could 
explain the varying culture success rates of HCV in this cell line.
1.2.2 HCV culture in primary hepatocytes
The use of primary chimpanzee or human hepatocyte culture systems for 
the production HCV could be more rewarding. Lanford et al infected chimpanzee 
primary hepatocytes, isolated from liver wedge biopsies, with an inoculum from 
an immunosuppressed HCV-positive heart transplant recipient. Using either 
tagged cDNA primers or thermostable reverse transcriptase, they first 
demonstrated HCV negative-strand RNA 4 days post-infection. It persisted for the 
duration of the experiment (25 days) but was cell associated with little RNA 
detected in the medium (Lanford et al, 1994). This is not unusual for viruses 
cultivated in vitro, but it is plausible that this culture system might not support a 
complete replication cycle. Moreover, the authors reported significant batch 
variation between hepatocytes taken from different animals with regards to their 
infectability.
21
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Fournier et al infected primary normal adult differentiated hepatocytes 
with 33 different HCV positive sera with various virus loads from three different 
genotypes. Intracellular negative strand RNA was detected in only 10 of the 33 
cultures, usually at day one post infection, rising at day five, then followed by a 
decrease at two weeks post infection. Conversely, positive strand RNA was 
detected in all cultures, but levels decreased after a few days, though remained 
detectable for up to eight days. There was no significant batch variation between 
hepatocytes taken from different individuals, they maintained their differentiated 
state and were metabolically active for up to 35 days; (demonstrated by active 
cytochrome P450). However, this culture system did not support the production of 
progeny virions in the culture supernatant (Fournier et al, 1998).
The use of HCV infected primary hepatocytes to generate a culture system 
was explored by Ito et al. Primary hepatocytes were isolated from liver biopsies 
taken from five patients with either liver cirrhosis or chronic active hepatitis. 
Using a competitive RT-PCR and negative-strand assay, HCV RNA was detected 
and quantified in cells and supernatant through out the culture period (14-56 
days). The culture supernatant was then used to infect HCV-negative primary 
hepatocytes. Double staining experiments for anti-HCV core and anti-human 
albumin antibodies, suggested that HCV replication was restricted to hepatocytes 
(Ito et al 1996). One of the disadvantages of using cirrhotic livers to generate this 
culture system is that the cell yield and viability is reduced (Kusano et al 1997), 
thus experiments are difficult to repeat.
Primary adult hepatocytes have a long life span and rarely divide. When 
kept in serum free medium supplemented with growth factors, they will undergo 
one or two rounds of replication without losing their differentiated state. They 
then tend to degenerate and die (Fausto et al, 1995). However, after priming with 
DMSO and epidermal growth factor (EGF) stimulates them to enter DNA 
synthesis after DMSO is removed. This process induces enhanced hepatocyte 
proliferation, which lasts for 2 days. Re-exposure to DMSO and EGF will induce 
the same response (Michalopoulos, 1990). This was exploited to induce infection 
of hepatitis B virus (HBV) in HepG2 (Gripin et al 1988), then applied to HCV
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culture in the infection of Huh7 cells (Seipp et al, 1997). Its use in promoting 
HCV infection in primary adult hepatocyte cultures has yet to be investigated.
Maintenance of differentiated primary adult hepatocytes has been explored 
in different culture systems in addition to growth in serum free chemically defined 
medium (Isom and Georgoff, 1984). The use of a three-dimensional collagen gel 
sandwich, for example, will allow the hepatocytes to remain differentiated for up 
to one year in culture (Blaheta, et al 1998), and thus could be used to investigate 
the life cycle of HCV.
Human foetal hepatocytes can remain differentiated. Iacovacci et al. 
detected HCV RNA negative-strand in cells and culture supernatant with an 
increase in HCV genomic templates for three months post-infection (Iacovacci et 
al, 1993). Free virus particles in the supernatant were later demonstrated 
(Iacovacci et al, 1998). But access to a reliable source of foetal cells can be 
difficult for ethical reasons, limiting their potential for generating continuous 
culture systems.
To overcome the cultivation restraints of primary hepatocytes, the 
development of conditionally immortalised human hepatocytes using simian virus 
40 (SV40) that can sustain HCV replication in vitro should be explored. Rodent 
hepatocytes can be successfully immortalised by SV40 (Nakamura et al 1997). 
But difficulties associated with special growth requirements of primary 
hepatocyte in vitro cultures can be eliminated in in vivo systems by the initiation 
of liver regeneration (Michalopoulos, 1997).
One of the main draw-backs of in vitro culture systems is that they are not 
useful for studying immuno-pathogenicity of disease.
1.3 Hepatocyte transplantation
1.3.1 Sugical transplantation
Surgical transplantation into a permissive site of an animal could be a 
more reliable method for cultivating primary hepatocytes. The intact liver can 
provide important physiological conditions, as its extracellular matrix will allow
23
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polarity to develop in the hepatocytes thus retaining their differentiated state 
(Sawa et al 1997).
Allogeneic and syngeneic ectopic hepatocyte transplantation (in to the 
portal vascular bed, through the spleen) has been successfully demonstrated in 
rodents (Sawa et al 1997). Recently, allogeneic human hepatocyte transplantation 
was also demonstrated by Fox and colleagues in a patient with Crigler-Najjar 
syndrome type I. The patient was treated with an infusion of primary hepatocytes 
(5% of the normal hepatocyte mass) through the portal vein (Fox et al 1998). The 
number of hepatocytes that can be transplanted safely is limited due to the high 
risk of a portal embolism and subsequent hepatic failure (Sawa et al 1997). 
Therefore, a suitable stimulus to elicit hepatocyte proliferation is a prerequisite for 
successful engraftment.
1.3.2 Liver regeneration
Hepatocyte proliferation can be attained by a partial surgical hepatectomy 
(Michalopoulos, 1997) or a chemical hepatectomy with either CCI4 (Sawa et al 
1997) or D-galactosamine (Dabeva et al 1993). These compounds will cause 
gradual liver injury and necrosis, which, in turn, will initiate liver regeneration. 
Further, DNA synthesis following the use of these compounds occurs 1-3 days 
after partial hepatectomy (Michalopoulos, 1997).
As a result of liver injury, there is increased secretion of mitogens and 
growth stimulants. The initial mitogenic stimulant after a partial hepatectomy is 
hepatocyte growth factor (HGF), which with its receptor c-met is a key factor in 
liver regeneration. HGF is detected in the plasma within one hour after a partial 
hepatectomy and in a rat its levels rise 20 fold then return to normal levels after 
72 hours (Michalopoulos, 1997). It is a potent mitogen for primary hepatocytes in 
culture (Fausto et al 1995). Other mitogens include EGF, tumour growth factor-a 
(TGF-a) and tumour necrosis factor-a (TNF-a), the latter stimulating the 
secretion of interleukin-6 (IL6) by Kupffer cells, that are also involved in liver 
regeneration. Insulin and noradrenaline are also important as they amplify the 
mitogenic responses to EGF and HGF (Michalopoulos, 1997).
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Generation of the mitogenic stimuli for hepatocytes depends on the 
integrity of many signalling pathways. These pathways and the tissue sources of 
origin are presented in Figure (2).
A proliferative stimulus can also be provided by means of gene transfer 
using a recombinant adenovirus vector that expresses a modified urokinase gene 
into hepatocytes of the recipient animal. This results in asynchronous hepatocyte 
degeneration, which is likely to be caused by intracellular conversion of 
hepatocyte derived plasminogen to plasmin. Plasmin is a protease that results in 
the activation of a number of proteins and is thought to be toxic within the cells. 
This will cause the proliferation of the donor cells, allowing the reconstitution of 
8.6% of the recipient’s liver (Peeters et al 1997). Alternatively, complete 
replacement of the recipient’s liver with the donor’s hepatocytes was 
demonstrated in the albumin-urokinase (Alb-Upa) transgenic mouse model, in 
which hepatocyte targeted expression of a hepatotoxic transgene creates a 
functional liver deficit, resulting in a chronic stimulus for liver growth. The model 
elegantly demonstrated successful transplantation of either normal mouse primary 
hepatocytes (Rhim et al, 1994) or rat primary hepatocytes (Rhim et al, 1995). 
These models have potential for developing a HCV animal model.
1.3.3 Artificial support for hepatocyte transplantation
The use of solid supports, consisting of either non-biodegradable synthetic 
fibres or biodegradable polymers, for in vivo culture of primary hepatocytes is 
another approach to transplantation. These provide a three-dimensional 
framework, allowing sufficient space for infiltrating hepatocytes to be exposed to 
the host’s environment. The cells can adhere to the framework, restoring the cell 
to cell and cell matrix interactions. When transplanted, they become vascularised 
and the cells regain their polarity (Arkadopoulos et al, 1997). Several examples of 
solid support include liver beads, which are living hepatocytes entrapped within 
an alginate matrix (Fremond et al, 1993); polytetrafluoroethylene (PTFE) fibres, 
which do not produce an intense inflammatory response and Cytodex 3 collagen 
coated micro-carriers. These can
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be transplanted into the peritoneal cavity or under the renal capsule of the animal 
(Arkadopoulos et al, 1997). But the number of hepatocytes attached to these solid 
support units is limited by the size of the animal. For example, liver beads only 
contain 400 cells/ bead (BIOPREDIC International, France), therefore to 
transplant 10 6 cells per site, will require around 2500 beads, making this an 
unpractical and expensive model. Further, to retain their differentiated state in 
vivo the hepatocytes would also require proliferative stimuli, to ensure their 
prolonged survival.
1.4 Animal models of infection
1.4.1 HCV infection in chimpanzees
The chimpanzee is the only successful animal model for HCV and was 
first used in infection and characterisation experiments for non-A, non-B hepatitis 
(Feinstone et al, 1981). To investigate early events in HCV infection, Shimizu et 
al successfully infected two chimpanzees intravenously with 0.5ml of undiluted 
plasma obtained from a patient with post-transfusion acute non-A, non-B hepatitis 
(Shimizu et al, 1990). RNA transcripts from full-length HCV functional clones 
were also found to be infectious and to cause disease when injected intra- 
hepatically into two HCV naive chimpanzees (Kolykhalov et al 1997).
The successful infection of chimpanzees with a single clone of HCV can 
provide a model where viral evolution and persistence can be studied (Yanagi et 
al 1997). Yanagi et al injected RNA transcripts from full-length cDNA clones of 
the H77 strain intrahepatically into 2 chimpanzees. Similar to earlier reports of 
HCV challenge in chimpanzees, HCV RNA was detected 8 weeks postinfection 
(Yanagi et al 1997). The disadvantages of these chimpanzee animal models are 
cost and ethics. Consequently, only a very limited number of animals can be used 
experimentally as a results accessibility of such a model for widespread 
experimental studies is restricted.
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1.4.2 Rodent infection models
Rodents have been used as an alternative model of HCV infection. 
Yamamoto et al transfected HCV cDNA into rodents via either the tail vessel or 
the portal vein using asialoglycoprotein receptor mediated gene delivery. This 
receptor is expressed on hepatocytes. The cDNA delivered codes for the core and 
part of the envelope protein of HCV; the core protein was detected in the liver by 
immunohistochemical techniques (Yamamoto et al 1995). The practicalities and 
applications of delivering full length infectious HCV RNA by this method should 
be investigated.
Transgenic mouse lines that express HCV proteins in the liver are 
alternative possible animal models. A cDNA fragment containing the entire HCV 
core gene was placed down stream of a transcriptional regulatory region from 
HBV. Two distinct lines were created. Southern blotting showed a distinct 
integration site. Expression of the core protein in the liver started at birth and 
continued for at least 19 months. These mice developed hepatic steatosis as early 
as 3 months and the long term consequences of this model was that some of the 
mice from both lines (25.9% and 30.8%) developed hepatocellular carcinomas 
(Moriya et al 1998).
1.4.3 Role of xenotransplantation in animal infection models
Xenotransplantation of permissive cells or tissue fragments has become 
one of the most frequently used methods for the construction of animal infection 
models. The severely combined immunodeficient (SCID) mouse accepts 
xenografts from a range of species including humans, because it lacks functional 
B and T cells resulting from defects in the T-cell receptor and an immunoglobin 
variable region (Bosma, et al 1983).
1.4.3 a) Transplantation of transfected cells or infected tissue
Transplantation of permissive cells into a SCID mouse transfected with an 
infectious clone is one example of xenotransplantation, which can be applied to 
construct an HCV animal model. In nude mice, transplantation of HepG2 cells
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transfected with the hepatitis B genome led to Dane particles and HBV antigen 
production in vivo (Zhai et al 1990). Alternatively, human/SCID chimeras can be 
infected with agents that can only replicate in human cells. This technique has 
been successful for other virus animal models, for example the human papilloma 
virus (HPV). An animal model was generated from grafting anogenital and 
laryngeal papillomas harbouring either HPV-6 or HPV11 (Sexton et al, 1995) and 
a cytomegalovirus (CMV) mouse model was generated from the transplantation 
of hemapoietic tissue inoculated with CMV (Mocarski et al 1993). Recently, 
Bronowicki et al tested HCV persistence in transplanted haemapoitic cells in a 
SCID animal model where PBMC from 14 HCV infected individuals with 
histologically documented chronic hepatitis, were injected intraperitoneally. After 
an eight-week follow up, 7 of 26 serum samples and 8 of 27 PBMCs were 
positive for HCV RNA positive strand. However, negative strand HCV RNA was 
only detected in 2 of the 10 mice tested, which were inoculated with PBMCs from 
patients with either non-Hodgkins’s lymphoma or acute lymphoblastic leukemia. 
(Bronowicki et al. 1998).
1.4.3 b) In vivo infection of transplanted cells
In vivo infection of transplanted permissive human cells was demonstrated 
in the malaria mouse model and could have potential applications in an HCV 
model. Here primary human hepatocytes were transplanted under the renal 
capsule and subsequent intravenous infection with Plasmodium falciparum 
sporozoites took place one week post- transplantation. The grafts produced a well- 
defined cell mass that was histologically distinct from the kidney and were also 
permissive to infection with P falciparum for up to 4 months post-transplantation 
(Sacci eta l 1992).
1.4.4 Shortcomings of SCID/human chimera
One disadvantage of the SCID/human chimera is that mouse mononuclear 
phagocytic cells are known to attack transplanted cells, thus preventing successful 
engraftment. This phenomenon was observed when HCV infected primary foetal
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hepatocytes were transplanted in SCID nude mice and were subsequently attacked 
two weeks post transplantation (personal communication, Dr Frederick Prince 
from the New York Blood Centre). However, to promote engraftment of donor 
human hepatocytes, mononuclear phagocytic cells can be removed by either the 
administration of silica to the mice after transplantation (Adno et al, 1993), or 
alternatively, liposome-mediated macrophage "suicide" technique can be applied, 
where the dichloromethylene diphosphonate is encapsulated. On ingestion of the 
liposomes, the macrophages will be destroyed (Van Roojen, 1989). This approach 
was applied to facilitate the successful engraftment of human hematopoietic cells 
in SCIDS. Histological examination of the spleen showed transient elimination of 
all macrophage subsets and unexpected graft failures were not observed (Terpstra 
et al, 1997).
Another disadvantage of the SCID mouse model is that its phenotype is 
known to develop populations of peripheral mature lymphocytes in a time and 
strain dependent manner; that is, they become "leaky". This may be due to 
somatic reversion events or to rescue of the liberated coding regions in SCID pre­
lymphocytes by alternative recombination mechanisms (McBride et al 1995). 
Consequently, some grafts may fail (Krensky, 1997).
1.4.5 Infection models in SCID Beige human/chimeras
SCID Beige mice are a potential substitute for SCID mice, for they lack 
natural killer (NK) cells and the beige defect results in defective lysosomal 
granule formation. This could allow successful engraftment and the establishment 
of viral infections (McBride et al 1995). Further, these mice are less prone to 
develop "leaky" individuals; in fact, less than 2% produce T cells or 
immunoglobulin (Krensky, 1997). Adult human PBMC can also be delivered into 
SCID/beige mice by intraperitoneal injection. This was demonstrated in the 
human immunodeficient virus (HIV) mouse model (McBride et al 1995). 
Secondary type immune responses, have also been exploited in protection studies 
involving adoptive transfer of PBMCs taken from volunteers immunised with 
vaccinia expressing HIV-1 LAV/Bru 160 Dalton envelope glycoprotein and
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subsequently given booster injections of recombinant gp 160 protein (Mosier et al 
1992). The passive transfer of human HIV specific antibodies into mice bearing 
human effector cells may lead to a better understanding of protective mechanisms 
involved (McBride.er al 1995).
Gallun et al used lethally irradiated Beige/nude /X-linked 
immunodeficient (BNX) mice that were intravenously injected with SCID mouse 
bone marrow. After transplanting human tissue, a mouse model that comprises 
three genetically disparate sources of tissue, a “trimera” in vivo model, will result 
(Gallun et al, 1995). The transplanted tissue used was human liver fragments from 
chronically infected HCV patients and uninfected persons, after ex vivo 
incubation with HCV serum. This was grafted under the kidney capsule.
In spite of the morphological changes reported in the grafts, HCV RNA 
was detected by RT-PCR in the serum from mice with liver fragments taken from 
3 patients with chronic HCV infection. This was first observed 2 weeks after 
infection and was detected intermittently for 2 months post-transplantation. A 
similar pattern was noted with the fragments infected pre-transplantation with 
HCV serum, with HCV RNA detected in 20-30% of the transplanted mice. Since 
the RNA negative-stand assay performed in the animals that received pre-infected 
liver fragments was positive, it is plausible that HCV replication had taken place 
in the transplanted grafts in vivo (Gallun et al 1995). A similar HBV “trimera” 
animal model was developed by Dan et al where BNX mice or (CB6F1) strain of 
mice that were thymectomised at 6-8 weeks were used. Transplantation of the 
grafts was either under the renal capsule or in the ear pinna and the animals 
remained viraemic for up to one month post-transplantation (Ilan et al, 1999).
"SCID-hu" chimera/trimera systems are limited by the absence of human 
macro- and microenvironments, the lack of soluble factors (including nutrients, 
cytokines, and hormones) and differences in matrix and cell surface interaction 
molecules. For these models are not physiological, and are of limited use for drug 
testing (Krensky 1997). To resolve some of the above deficiencies Sultan and his 
colleagues developed a variation of the “hu/ PBL/SCID” system to study 
transplantation rejection. This was achieved by grafting human skin on to SCID
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beige mice and then followed by an intraperitonel injection of adult lymphocytes. 
This model did not represent true allogenic rejection, but was useful to study 
molecular and cellular interactions (Sultan et al 1997). It is plausible therefore, 
that the “hu/PBL/SCID” rational can be applied to an HCV infection animal 
model. One approach is where primary human hepatocytes are transplanted 
intrasplenically, the animal is then injected with syngeneic PBMCs and 
subsequently infected in vivo with HCV positive serum.
To date all rodent HCV infection models have failed to replicate natural 
HCV infection, though intermittent negative strand RNA was demonstrated in 
transplanted ex vivo infected liver fragments by Gallun et al indicating a small 
window of viral replication. Therefore, long term testing of drug strategies in this 
model will be limited.
Apart from the technical difficulties in establishing this model, 
cryopreservation of whole liver fragments is still experimental. Additionally, 
there will be considerable batch variation, as the material used originates from 
different donors.
The absence of HCV negative strand RNA in circulating PBMCs 
demonstrated by Laskus et al questions HCV lymphotropism and the use of T 
cells as potential permissive sites for viral replication. It is possible that HCV has 
lymphotrophic and hepatotropic tendencies, since CD 81 receptor that binds the 
HCV envelope protein is expressed on PBMCs as well as hepatocytes. Or that 
PBMCs are important in that they act as chaperones for HCV infection.
Transplantation and in vivo infection of hepatotropic cell lines that are 
permissive to HCV infection in vitro and primary human hepatocytes has not been 
documented to date. This approach if successful can demonstrate a repeatable and 
easily accessible model for primary and acute HCV infection and thus can be used 
to test drug strategies.
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1.5 Aims and experimental approach
The aim of this project is to establish a reproducible in vivo cell culture 
system that would support the complete replication cycle of HCV.
Huh7, HepG2 and WRL68 cell-lines, cryo-preserved primary human 
hepatocytes from liver that cannot be placed for transplantation and cryo- 
preserved primary human hepatocytes obtained from HCV positive explant livers 
will be transplanted into SCID mice after performing a partial hepatectomy. These 
cells will be infected with HCV positive serum from the same HCV infected 
individual by either intra-venous or intra-peritoneal routes. Ex vivo infection will 
also be attempted prior to transplantation.
To test successful engraftment of the cell-lines, paraffin fixed sections will 
be examined using hematoxylin and eosin staining. However, detection of human 
primary hepatocytes will require cytokeratin 18 staining and albumin detection 
using immunocytochemistry and in situ hybridisation techniques.
The animal tissues and whole blood will also be tested for the presence of 
HCV using positive strand RT-PCR at time intervals.
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CHAPTER 2
Materials
All chemicals and reagents were purchased from BDH Chemicals UK or 
from Sigma-Aldrich Company Ltd UK, unless otherwise stated.
2.1 Animals
Mice: Sex: male; Strain:CB-17 SCID ( on ICR Background) 
(Harlan UK Ltd)
2.2 Surgical instruments and reagents
Instruments Microfine Scissors, HB-040-01-J Scissors, Microfine Forceps 
(B.Brone, Downs Surgical, UK); Insulin syringes: 1ml 2.7mm 
Microfine U-100 (B D Microlance, Becton Dickinson, UK); 
Scalpel blades (Swann Morton, UK); Sutures: Vicryl 3/0 code 
W94444, Mersilk 5/0 code W580 (Ethicon, UK).
Reagents Halothane (Zeneca Ltd, UK).
2.3 Explant Livers
Professor James Neuberger from the Liver and Hepatobiliary Unit, Queen 
Elizabeth Hospital Birmingham, supplied five HCV positive explant liver wedges 
from the left lobe of HCV positive transplant recipients.
(a) Donor 1, age 46 years, patient also had alcohol related liver disease. Date 
received was 20/8/97.
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(b) Donor 2 age 40 years, date received was 14/1/98.
(c) Donor 3 age 57 years, date received was 21/4/98.
(d) Donor 4 age 46 years, date received was 7/7/98.
(e) Donor 5 age 67 years, date received was 14/1/99.
There was no HCV subtype data available on the above donors.
Mr Bryon Jaques at the Transplant Unit, Addenbrookes Hospital, 
Cambridge supplied wedges from three livers that could not be placed for 
transplantation:
(f) Donor 6 age 7 years, date received was 17/5/98.
(g) Donor 7 age 56 years, date received was 3/6/98.
(h) Donor 8 age 8 years, date received was 14/6/98.
A ninth liver obtained from a 42 year old woman was received on 29/5/98 
and supplied by Mrs Walsh, the transplant coordinator at the Renal Transplant 
Unit, at the Western Infirmary Glasgow.
Donors 6 and 8 tested negative serologically for HBV, HCV, HIV and
CMV, but donor 7 was positive for CMV. No serological tests were available
from the ninth donor.
2.4 Human sera
Various staff members of the lab 109 donated negative (control) sera 
during the project.
Dr Douglas Thorbum supplied HCV antibody positive successive sera 
from an asymptomatic patient, 001, (without severe liver disease) attending the 
Liver Clinic at Gartnavel Hospital, Glasgow.
HCV antibody positive serum from a patient with cryoglobulinemia/ 
macronodular liver disease was titrated to 107 copies/ ml HCV by Adna Ochert, 
Roche Discovery, Welwyn Garden City, UK. This was obtained from Sacramento 
Blood Center and supplied by Roche Discovery, Welwyn Garden City, UK.
Pelispy HCV-RNA run control, is a weak positive plasma standard for the 
validation of HCV-RNA amplification test runs. It contains 3800 genome
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equivalents /ml and was obtained from Central Laboratories of the Netherlands 
Red Cross Blood Transfusion service.
2.5 Cell lines
HepG2 (Aden et al, 1979; Knowles et al, 1980) and WRL68 (Apostolov, 
1976; Gutierrez et al, 1994) cell-lines were obtained from the European 
Collection of Animal Cell Cultures, PHLS, Center for Applied Microbiology and 
Research Department, Porton Down, UK. The Huh7 (Nakabayashi et al, 1982) 
cell-line was available for use at the Institute of Virology, University of Glasgow.
2.6 Buffers, Solutions and Materials for the following procedures:
2.6.1 Liver Perfusion
Krebs-Henseleit (KH) solution
117mM NaCl, 2.4mM NaHCC>3 , llm M  Glucose, lOmM Hepes, 4.7mM
KC1,1.2mM MgS04 .H20 , and 1.2mM KH2P 0 4.
Buffer A A 10 mM solution of EGTA was prepared with the KH
stock solution; pH was adjusted to 7.4 with 0.1 M NaOH.
Buffer B This was prepared by diluting the KH solution with H20
(1/4 v/v); pH was adjusted to 7.4 with 0.1M NaOH.
Buffer C A  4.2 mM solution of CaCl2 was prepared with the KH
stock solution, pH was adjusted to 7.6. This was then used 
to produce a 0.5mg/ml Collagenase D solution (Roche 
Diagnostics, UK).
Buffer D A 0.75mM solution of CaCl2 was prepared with the KH
stock solution.
All buffers were supplemented with 40mg/ml Gentamicin (Life
Technologies Ltd UK).
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Marseilles’s Freezing Medium
L I5 Medium (Life Technologies Ltd, UK) containing 2% 
(v/v) Polyvinylpyrrolidone (PVP) 2.5% (w/v) Bovine 
Serum Albumin fraction V, 20% Foetal Calf Serum (FCS) 
(Advance Proteins Products, UK) and 10% Dimethyl 
Sulphoxide.
Isotonic Solution 0.15M NaCl, 0.4 mM Na2HP04, 0.3 mM KH2PO4,1.0mM
M gS04> 2.0 mM CaCl2, 20mM Hepes-NaOH (pH 7.5).
Nycodenz Gradient 40%(w/v) Nycodenz containg 6.5 mM KC1, l.OmM CaCl2t
lOmM Hepes-NaOH (pH 7.5).
2.6.2 In vivo and in vitro culture medium
Cell lines
Dulbeco’s modified essential medium (DMEM) 100IU/|xl Penicillin, 100IU/|il 
Streptomycin, and 2mM L-Glutamine (Life Technologies Ltd, UK), 10% Foetal 
Calf Serum (Advance Proteins Products, UK) trypan blue, Trypsin, Versene, 
(supplied by the media service at the Institute of Virology, Church Street, 
Glasgow).
Primary Hepatocyte Transplantation
DMEM, Bovine serum albumin (1%), 0.02|ig/ml EPG, lOU/ml Insulin, lOOOU/ml 
Interleukin 6 (Roche Diagnostics, UK), 60pg /Animal Anti -met antibody supplied 
by Ken Hillan (Genentech, USA), 38.5mg/ml, Silica and Silicon discs, known as 
Immobasil D (Integra Biosciences, UK).
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2.6.3 General Pathology use
Harris Haematoxylin, Putt’s Eosin, Paraffin wax, and Trigene were 
purchased from R and J Lamb, UK; Goat serum was obtained from Scottish Anti­
body Production Unit, Law Hospital, Glasgow; Formol saline, Hydrogen 
Peroxide/ Methanol (1/60), Tris buffered saline, 0.01M Citrate buffer, Tween 20, 
Xylene.
Scotts tap water (STW) 3.5g sodium hydrogen carbonate, 35.7g magnesium
sulphate dissolved in one litre of water.
Apes coated slides Slides immersed in a 2% solution of 3’-
aminopropyltriethoxysilane/ acetone and dried at 
60°C.
2.6.4 In situ Hybridisation and Southern blot Hybridisation
All reagents were prepared with Diethypyrocarbonate (DEPC) treated ultra pure 
H20  (Elga UHP).
Denhardt’s Reagent, X50
5g Ficoll (Type 40), 5g PVP, 5g Bovine serum albumin 
dissolved in DEPC treated H20  to a final volume of 
500mls.
20 X  SSC 3M NaCl, 0.3MNa3C6H5O7 (pH7.2).
Denaturation Solution
1.5MNaCl, 0.5MNaOH.
Neutralisation Reagent
1.5MNaCl, 0.5MTris-HCl pH7.
Pre Hybridisation solution
5XSSC, 50% deionised Formamide
Hybridisation solution
5M Tris pH7.5, 10X Denhardt’s, 2X SSC, 0.5% SDS, 50% 
deionised Formamide, 10% Dextran Sulphate 20pg/ml 
sonicated Salmon Sperm DNA.
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Hybond N(+) Membrane (Amersham, Pharmacia Biotech, UK).
X-OMAT S film (Kodak Ltd, UK)
The following reagents were used in in situ Hybridisation only:
End-labelling o f probe reagents
Biotin-16-dUTP, (Roche Diagnostics,UK), dCTP
(Amersham Pharmacia Biotech, UK), 5X tailing buffer 
(Life Technologies Ltd, UK).
Digestion and fixing reagents
HCL, TritonX and Paraformaldehyde.
Dig(l) buffer lOOmM Tris base, lOOmM Tris HC1, 150 mM NaCl pH 7.6.
Dig(3) buffer lOOmM Tris base, lOOmM Tris HC1, 150 mM NaCl pH 9.5.
Visulisation Reagents Stock solutions
Nitro Blue Tetrazolium (NBT): 7.5mg/ 100|il 70% 
Dimethyl Formamide; Bromo-Chloro-Indoly-Phosphate 
(BCIP): 5mg/100jil 100% Dimethyl Formamide;
Levamisole : 2.3mg dissolved in lOjxl Dig (3) buffer.
NBT/BCIP Levamisole working solution
10ml Dig(3), lOpl Levamisole stock solution, 34jll1 BCIP 
stock solution and 44|il NBT stock solution, the solution 
was mixed filtered and stored at 4°C.
2.6.5 Immunocytochemical staining (ICC)
Antibodies
Anti-mouse monoclonal against cytokeratin 8 and 18 antigens (Novocastra
Laboratories Ltd, UK).
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Anti-rat peroxidase monoclonal and Anti-digoxigenin, Fab fragment from sheep 
conjugated with alkaline phosphatase (Roche Diagnostics,UK).
Alfa fetoprotein rabbit anti-human polyclonal; swine antigen anti-rabbit 
biotinylated polyclonal and rabbit antigen anti-mouse polyclonal, mouse 
peroxidase anti peroxidase (PAP) antibody (Dako Ltd, UK).
Anti-rat monoclonal against murine macrophage lineage (F4/80) was a generous 
gift from Dr Jim Brewer at the Department of Immunology, Glasgow University, 
but also can be obtained from Sero Tec, UK.
General visulisation Reagent
3,3 Diaminobenzidine Tetrahydrochloride (DAB)
2.6.6 RNA extraction
All reagents were prepared with DEPC treated molecular biology grade H2O.
Stock solution D (450g in 293ml H2O) Guanadinium isothiocyanate,
(26.4ml) of 10% N-lauryl sarcosine, 17.5ml of (0.75M) 
NaaCeHsOv 2. H2O filtered with a 2pm filter.
Lysis Buffer 180pl p- Mercapthoethanol in 25ml stock solution D.
Other reagents RNA carrier (yeast tRNA), 2M CH3COONa, Phenol,
Chloroform, Isoamyl alcohol and Ethanol.
2.6.7 RT-PCR analysis
50mM MgCL, 10X PCR buffer, 5XRT buffer, DTT and lOObp Ladder were all 
purchased from Roche Diagnostics,UK Taq Start ™ Antibody (Clontech 
Laboratories Inc., Palo Alto CA) mineral oil.
lOXdNTPs lOOmM each of dATP, dTTP, dCTP, dGTP (Roche
Diagnostics,UK).
10 X  TBE 89mM Tris base, 89mM Boric acid, lOmM EDTA.
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Gel loading buffer 50% Glycerol, 0.025% Bromophenol blue (1%) IX TBE.
Agarose Gel 1.5% Agarose in IX TBE buffer, 50|il (lmg/ml) Ethidium
Bromide per 300mls of Agarose.
2.7 Plasmids
pGEM3Zf(-) containing a 2Kb cDNA sequence of Human Albumin obtained 
from ATCC Rockvile, Maryland, USA.
pBSK9 containing 5’UTR, Core, E l and E2 regions of HCV (Nucleotides 1- 
2545) synthesized in Roche Discovery, Welwyn Garden city, UK.
2.8 In situ plasmid Linearisation Buffers
lOXNTPs lOmM each of ATP,CTP,GTP and UTP ( 6.5nM) and Dig labeled 
UTP (3.5 nM) (Roche Diagnostics,UK)
5X Transcription buffer (Roche Diagnostics,UK).
2.9 Kits
Vector VIP Peroxidase Substrate Kit (Vector Laboratories, UK).
Universal Vectastain ABC Kit (Vector Laboratories, UK).
ECL Random prime labeling kit (Amersham Pharmacia Biotech, UK).
2.10 Enzymes
Proteinase K, DNase I, RNase free, SP6 RNA polymerase, EcoRI restriction 
endonuclease were purchased from Roche Diagnostics,UK.
Taq™ DNA Polymerase ,Reverse Transcriptase M-MulV, Rnasin RNase inhibitor 
were either purchased from Roche Diagnostics,UK or Life Technologies Ltd, UK 
Terminal deoxynucleotidyl transferase was purchased from Life Technologies 
Ltd, UK.
2.11 Oligonucleotides
Oligonucleotides are summarised in tables 2.1 and 2.2:
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Methods
3.1 Perfusion of normal and HCV infected human explant livers
Livers and lobes were obtained from HCV positive transplant recipients or 
perfused normal donors, whose livers could not be used for organ transplantation. 
All HCV positive liver explants were perfused with University of Wisconsin 
(UW) preservation solution after hepatectomy. Normal livers were perfused in 
situ prior to hepatectomy. A portion of the organ, usually the left lobe (300g- 
500g), was resected, then transported in UW preservation solution on wet ice and 
processed usually within 24 hours.
The tissue was processed aseptically in a class II hood under category III 
containment level in accordance with the health and safety regulations.
To isolate primary hepatocytes, digestion of the liver was performed using 
four perfusion buffers A, B, C and D in succession: (chapter 2, section 2.6.1), 
prepared shortly before processing and stored at 4°C. Just prior to processing the 
tissue, the buffers were allowed to equilibrate to 37°C. Starting with buffer A and 
using a cannula, 500 mis of each buffer were injected through a suitable vein in 
the tissue with a 50ml syringe (flow rate was approximately 20-30ml/minutes). 
The objective of perfusing with a pre-perfusate (buffer A) was, to wash out the 
remaining blood from the liver and to remove Ca 2+, which is a cellular adhesive 
ion. The EGTA in this solution is a chelator of Ca 2+removing extracellular Ca 2+. 
Buffer B washes out any residual buffer A. Buffer C contains collagenase, which 
is a crude extract from Clostridium histolyticum and includes various proteolytic 
enzymes which act effectively to disperse cells. The enzymatic activity of
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collagenase is Ca 2+ ion dependent and maximum activity is obtained with a 
perfusate containing 4 mM Ca 2+. To disperse the cells the lobe was then washed 
in buffer D (Kasai and Mito, 1997) and the cells released by mechanical scraping. 
The tissue was then cut into fragments of 2 cm and a spatula used to release cells 
mechanically into a suspension of buffer D. The original cell suspension was 
filtered through gauze and washed twice by slow centrifugation (50 rpm). Cell 
count and viability was determined by trypan blue exclusion.
3.1.1 Cryo-preservation and storage of cells
Using Marseilles’s medium the hepatocytes were suspended at a cell density 
of 107cell/ml, aliquoted in sterile polypropylene vials and placed in either a 
Nalgen cell freezing storage container in the presence of propan-2-ol. Where the 
vials were placed initially at -70 °C for 24 hours, after which they were 
transferred to liquid nitrogen for long time storage. Alternatively, the vials were 
transferred to a cell-freezing machine (model Planer, KRYO10 HI Series). The 
freezing cycle was monitored, the optimum gradient temperature was - 
1.9°C/minute from 4°C to -30°C (2 in figure 3.1) and -30°C/ minute from -30°C 
to -150°C (3 in figure 3.1). Cryopreserved hepatocytes were stored at -196°C in 
liquid Nitrogen.
3.1.2 Preparation of primary hepatocytes for transplantation
Frozen ampoules were thawed quickly in a 37°C water bath; cells were 
suspended in isotonic buffer and centrifuged at 1000 rpm for 10 minutes. In 
some experiments, the cells were layered on a Nycodenz gradient and 
centrifuging at 1500rpm for 10 minutes at room temperature to further remove 
non-parenchymal and damaged cells. The cells were removed at the interface, 
washed in L15 medium and resuspended in either phosphate buffered saline 
(PBS), or hepatocyte growth medium (DMEM, 1% Bovine serum albumin 
0.02|ig/ml EGF, lOU/ml Insulin). A sample of the cells was also preserved in 
formal saline and cytospin preparations were made for immunocytochemical 
staining and in situ hybridization analysis, using a Shandon Cytospin 2.
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In some experiments, 3 x l0 6 cells were mixed with either Interleukin-6 (IL6) 
(100U) or with anti-met antibody (14|il), which is equivalent to 60pg/ animal. In 
another set of experiments, 3x10° cells were also mixed with both IL6 and anti­
met antibody.
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3.1.3 Preparation of transformed human hepatocyte cell lines
106 cells were seeded in a T 175 flask in 20ml DMEM medium supplemented 
with 10% FCS, 2mM L-glutamine, 100 IU/pl penicillin and 100 IU/pl 
streptomycin. The cultures were incubated at 37°C in the presence of 5% CO2 
and allowed to reach confluence. The cells were harvested using trypsin: versene 
at a ratio of 1:1 and suspended in PBS for transplantation. Alternatively, 105 
cells were seeded on to Immobasil D silicon disks, placed in 2cm tissue culture 
grade petri dishes and allowed to proliferate and infiltrate the matrix for 36 
hours. The disks were then removed and suspended in PBS for transplantation. 
Proliferation of the cells was determined by treating the disks with trypsin: 
vesene at a ratio of 1:1 and washing with PBS to release the adhering cells. The 
disks were also preserved in formol saline and processed after embedding in 
paraffin for microscopic examination.
3.1.4 In vitro infection of cells for transplantation
To infect the cells, HCV positive serum neat or 20% v/v with normal serum 
was mixed with 107cell/ml, suspended in either DMEM medium or hepatocyte 
growth medium, incubated at 37°C and agitated intermittently for one hour. The 
cell suspension was then administered into the animals.
3.2 Transplantation: surgery and anaesthetics
All procedures were performed in a class II hood under category m  
laboratory conditions in accordance with health and safety recommendations 
and the Animals (Scientific Procedures Act 1996).
3.2.1 Pre-surgical preparation and anaesthesia
5-6 week old mice were acclimatized to the positive pressure isolator 
(appendix 1) for one week prior to surgery.
Surgical instruments, swabs and drapes were sterilised at 121°C and 15psi 
for 20 minutes. The hood was sequentially disinfected with 2% Virkon and
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70% ethanol spray. A sterile drape was used to cover the operating area in the 
hood. The animals were shaved approximately 24 hours before surgery.
To induce anaesthesia, the animals were placed in a chamber where a 
mixture of oxygen and halothane vapour (2% v/v) was delivered from an 
anaesthetic machine (appendix 2). Maintenance of anaesthesia was achieved 
during surgery by inserting the animal’s head in a mask attached to the 
anaesthetic machine, from which a mixture of oxygen and halothane vapour 
at a concentration of 1-1.5% was delivered. Sufficient depth of anaesthesia 
was sustained; vital signs for example breathing and mucous membrane 
colouration and the pedal withdraw reflex were frequently monitored. The 
animals were placed with limbs restrained on a heated pad to maintain body 
temperature during surgery, in a supine position, swabbing with 70% ethanol 
to disinfect the skin.
3.2.2 Surgery
To expose the peritoneum and the abdominal cavity, a midline laparotomy 
incision was made (figure 3.2; solid line) using a size 15 scalpel blade. A 
further incision extending from the right border of the sternum, along the 
xiphoid process (figure 3.2; interrupted line) was made using scissors, taking 
care to avoid accidental penetration of the chest cavity (curved lines represent 
costal margins) (Doerr etal., 1990).
Exposure of the liver was achieved by manual compression of the thorax. 
The four major lobes were identified (right, median, left and caudate); the 
two segments of the median lobe are partially divided by the gallbladder 
(figure 3.3) (Doerr et al., 1990).
A 4/0 silk suture was used for mass ligation of the lateral portion of the 
median and right lobes (figure 3.3) avoiding the gallbladder, extrahepatic 
biliary tree, abdominal aorta and portal vein (figure 3.4a). The right lobe and 
the lateral segment of the median lobe were resected with scissors (figure 
3.4b). After haemostasis was obtained, the liver was gently eased back into 
the abdominal cavity.
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Both kidneys and spleen were individually exposed through the incision and 
supported in position. Cells were then injected under both renal capsules (106 
cells/ 50pi volume) and into the spleen using either a 25-gauge (G) needle or 27G 
insulin syringe (figures 3.5a and 3.5b).
In some experiments transplantation of cells was performed by inserting inert 
silicon disks containing cells into the abdominal cavity close to the liver.
In macrophage depletion experiments 200|il of silica (38.5 mg/ml) was 
injected into the peritoneal cavity. To restore the anatomical integrity of the 
muscle and skin layers a continuous suture pattern with either catgut or vicryl 
sutures was used (Waynforth and Flecknell, 1992).
3.2.3 Post-operative care
The animals were allowed to recover in a sterile cage placed on a heated 
mat. Vital signs such as breathing and colour of mucous membranes were 
monitored until the animal recovered consciousness. It was then returned to the 
negative pressure isolator (appendix 1). If, however, there was excess bleeding 
during the surgery, lOOjils of 0.18% isotonic saline was injected subcutaneously.
3.2.4 In vivo infection of transplanted cells
After 24 hours post-operative recovery, the animals were again 
anaesthetized; 50p,l of HCV positive serum was injected either intraperitoneally 
(IP) or intravenously (IV) using the tail vein with a 27G needle.
3.2.5 Phlebotomy
After anaesthetizing the animals, a small incision was made in the base of 
the tail using a 15-scalpel blade. The blood was encouraged to flow by applying 
pressure from the base to the tip of the tail. 50pl of blood was aspirated using a 
micropipette and mixed with sodium citrate (1/10 dilution).
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Figure 3.2 A drawing of a mouse midline laparotomy incision.
Solid line represents the scalpel incision, interrupted line 
represents the second incision made with scissors.
Taken from Doerr et a l 1990.
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MOUSE LIVER
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Figure 3.3 Drawing of the inferior surface of the liver The drawing shows 
the gallbladder (GB) and four lobes with relative percentages of 
total by weight. Taken from Doerr et a l, 1990.
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Figure 3.4 (a) Silk ligature in situ for resection of the right lobe and
lateral segment of median lobe.
(b) Resection of right lobe and lateral segment of median 
lobes with scissors, avoiding the gallbladder (arrow).
Figures 3.5 (a) Transplantation of cells under the renal capsule
(b) and into the spleen.
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3.2.6 Euthanasia and post-mortem examination
The animals were sacrificed by dislocation of the cervical vertebrae using 
standard protocols (the Animals Scientific Procedures Act 1996).
To perform the post-mortem examination, a mid-line incision was made with 
a 15-scalpel blade and scissors. The abdominal organs were exposed; small 
samples of fresh tissue for RNA analysis (approx.20-40mg) were taken from the 
spleen, kidney and liver. The samples were placed in sterile eppendorf tubes, with 
400|il of RNA lysis buffer (chapter 2, section 2.6.5) where they were macerated 
with a plastic pestle to ease tissue lysis, and stored at -702 C. Blood was collected 
from the thoracic cavity and heart using a 21G needle (200-300pl) and stored in a 
sterile eppendorf tube with 400|il RNA lysis buffer at -70 2 C.
The abdominal and thoracic organs, myocardium and lungs were eviscerated 
and placed in a jar containing 30ml of formal saline to fix for 24 hours for 
histological processing.
3.3 Pathological processing of fixed tissue
Specimen pots were transferred from the category IE laboratory to the 
pathology laboratory using all appropriate safety protocols, and immersed in Trigene 
disinfectant for 24 hours.
The abdominal and thoracic organs were examined grossly and any 
abnormality, in particular, the presence of tumor was noted. The liver, spleen, 
kidneys, heart and lungs dissected out; suitable blocks were selected for histological 
examination and processed to paraffin wax (appendix 3).
Using a Leitz microtome (model 1212), 3 \im  sections were cut, dewaxed and 
stained with Harris’s Haematoxylin and Putt’s Eosin (H&E) for routine microscopic 
examination. APES coated slides were used to aid tissue section adhesion for 
immunocytochemical staining and in situ hybridization.
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3.4 Immunocytochemical staining (ICC)
The following method was adapted from the standard operating procedures of the 
Department of Pathology, Western Infirmary, Glasgow and was used for the 
detection of cytokeratin 18 and 8, F4/80 and alpha feto protein antigens.
The sections were dewaxed and hydrated and endogenous peroxidases were 
blocked with 3% aqueous H2O2 solution. Antigen retrieval was performed using the 
microwave method with 0.01M citrate buffer (pH 6.0) and the power set at 750 W 
for three 5 minute cycles (Pileri et al, 1997). After which the sections were blocked 
with 20% normal goat serum for 10 minutes. No antigen retrieval was required for 
sections stained with Alpha feto protein polyclonal antibody. Primary antibodies 
were applied to the sections at the following dilution and allowed to incubate over 
night at 4°C:
• (1/100) Cytokeratin 18 and 8 mouse monoclonal.
• (1/200) F4/80 Macrophage mouse monoclonal.
• (1/500) Alpha feto protein polyclonal
The sections were then washed with TBS/Tween buffer 3 times at 5 minutes 
intervals. A secondary antibody at a 1/50 dilution (rabbit anti-mouse polyclonal, for 
Cytokeratin antigen detection), (anti-rat peroxidase monoclonal, for F4/80 detection) 
and (biotinylated swine anti rabbit polyclonal, for Alpha feto protein antigen 
detection) was applied and incubated for 30 minutes at room temperature. Sections 
were washed again with TBS/Tween buffer 3 times at 5-minute intervals. 
Cytokeratin stained sections were also incubated with mouse peroxidase anti 
peroxidase (PAP) antibody for 30 minutes at room temperature. The Avidin- biotin 
complex (ABC) was applied to the sections stained with biotinylated antibodies 
(following manufacturers instructions of the vector ABC kit). Finally, all sections 
were washed as before and visualization of the antigen was performed using either 
the vector VIP kit for the peroxidase-conjugated antibodies or DAB for the biotin- 
conjugated antibodies. The sections were then examined microscopically, counter 
stained with Harris’s Haematoxylin, dehydrated and mounted with Histomount for 
analysis.
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3.5 In situ Hybridisation
The following method was adapted from the standard operating procedures of the 
Department of Pathology, Western Infirmary, Glasgow, and was used for the 
detection of human albumin (hAlbumin) (Hillan, 1990).
A 2 Kb cDNA fragment (5p,g) corresponding to part of the coding sequence 
of human albumin was ligated into a pGEM3Zf(-) plasmid. l|ig  was then linearised 
with 10  units of EcoRI restriction endonuclease for 3 hours at 37°C. After 
purification with phenol/chloroform, the digest was then visualised on a 1 % agarose 
gel against uncut plasmid. lp,g of linearized plasmid was used to produce a 
Digoxigenin 11UTP labeled anti-sense riboprobe: the reaction was set up with 4jnl of 
5x transcription buffer, 2p,l DTT, 0.5pl RNASin, 2jil 1 0  xNTP and 2jll1 SP6 in a 20jil 
reaction volume.
The sections were dewaxed and hydrated, immersed in 0.02N HC1 for 15 
minutes at room temperature, washed in DEPC PBS, 3% TritonX 100 solution for 15 
minutes at room temperature; followed by lOOjig/ml Proteinase K digestion at 37°C 
for 25 minutes. The hAlbumin probe was applied to the sections and hybridized 
overnight at 42 °C using the Hybaid Omnislide chamber. Cover slips were used to 
prevent dehydration of the sections during the process.
Stringency washes were performed at room temperature using 2X SSC buffer 
for 30 minutes, followed by 0.1X SSC at 50 °C for 30 minutes. Alkaline Phosphatse 
conjugated anti-Digoxigenin antibody (1:200) was applied to the sections for 1 hour 
and washed off with Tris buffered saline. The probe was visualized using Nitro-Blue 
Tetrazolium/ Bromo-Chloro-Indolyl-Phosphate (NBT/BCIP) substrate and 
Levamisole. The slides were washed counterstained with Haematoxylin and mounted 
in Glycergel.
3.6 RNA extraction
200|xl of serum/ plasma mixed with 600 |il of RNA lysis buffer, or 400|il of 
lysed tissue mixed with 200|il of RNA lysis buffer were combined with ljxl of tRNA
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(lOjig/pl), 600pl phenol, IO O jllI chloroform and 50|il of 2M CH3 COONa and 
vortexed vigorously for lOminutes. The tubes (1.5ml) were then spun at 8000rpm for 
15 minutes, after which the aqueous phase was transferred to a fresh tube with 600fxl 
of chloroform and spun for 15 minutes at 8000rpm. The aqueous phase was then 
transferred to 600|il of propan-2-ol and the RNA was allowed to precipitate at -20°C 
overnight, after which the mixture was spun for 30 minutes at 14000rpm. The pellet 
was washed with 70% ethanol, dried, suspended in 20jil of DEPC treated water and 
stored at -70°C (Chomczynski and Sacchi, 1987).
3.7 Oligonucleotide synthesis and purification
Oligonucleotides were made “in-house” using a Cruachem PS250 synthesizer, by 
Mr David Macnab and Mr Alex Orr at the Institute of Virology, University of 
Glasgow. The DNA was covalently linked on a column to an inert support. To 
remove the oligonucleotides from the resin, they were cleaved with molecular 
biology grade ammonia solution (1.5M) through a 5ml syringe, subsequently 
deprotected at 55°C for 5 hours and dried overnight in a centrifuge evapourator 
(Sarant “speedivac” concentrator). The pellet was resuspended in lOOpl DEPC 
treated water.
3.8 Quantitation of DNA/RNA by spectrophotometry
RNA and DNA were quantified by reading the optical density (O.D) at 260nm 
using a Beckman DU-62 spectrophotometer. The following formula was used to 
determine nucleic acid concentration:
Concentration (|ig/ml) = O.D260nm x reading x dilution factor.
One O.D260 = 50pg/ml Double stranded DNA, or 40|ig/ml single stranded DNA or 
RNA or 20pg/ml for oligonucleotides(<30 bases in length)
3.9 Reverse Transcription (RT)
100 units of M-MLV Reverse Transcriptase were used to synthesise first strand 
complementary DNA (cDNA) from either 3 |il of extracted RNA or lpg extracted
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RNA/ reaction mixture. The reaction mixture contained 4|il of 5x first strand 
buffer; 3mM MgCl2; lOMm DTT; ImM each of dGTP, dATP, dTTP, dCTP; 
40pmol of HCV specific antisense primer and 1 unit of RNAsin in a final volume 
of 20|il. Incubation was for 60 minutes at 37°C and 95°C for 10 minutes and 
subsequently stored at 4°C.
3.10 Nested polymerase chain reaction (PCR)
3.10.1 First round PCR
The reaction mixture for the first round contained: 0.5 units of Taq DNA 
polymerase mixed with Taq start antibody (according to manufacturers 
instructions) in 2fil of lOx (Tris/KCl) buffer supplied by the manufacturer; 
1.5mM MgCl2 0.2mM each dGTP, dATP, dTTP, dCTP; and 16pmol each of the 
outer pair of primers, VICTAG-1/ VICTAG-940 (Table 3.1) in a final volume of 
20pl. The reaction was overlaid with lOjul of mineral oil to prevent evaporation 
and 4|il of cDNA product was then added. Amplification conditions are 
summarised in Table 3.1.
3.10.2 Second round PCR
ljul of first round product was amplified in a second round PCR using the same 
reaction mixture described above but using 16pmol of each inner primer 
VICT AG-3/ NCR4 (Table 3.1) in a final volume of 20pl. Taq start antibody was 
used to provide an automatic “hot start”. The PCR was performed on a Biometra 
TRIO Thermoblock. Amplification conditions are summarised in Table 3.1.
3.11 Agarose gel electrophoresis
Analysis of PCR results was by electrophoresis of lOpl of PCR product 
with 2|il of loading buffer on a 1 .5%  agarose gel containing 50jll1 (1 mg/ml) 
ethidium bromide. The gel was visualised under short wave UV light (254nm).
The following methods were used by Roche Discovery laboratory as part of a 
collaboration with our laboratory.
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Number of PCR Temperature
Primercombination amplification cycles /Time
1 95 °C /4 minutes
30 94 °C / 30 seconds
VICT AG-1/ 30 55°C /40 seconds
VICT AG-940 30 70 °C/2 minutes 30
First round PCR 1 seconds
pause 70°C/ 7 minutes 
10°C/
1 94 °C /5 minutes
VICT AG-3/ 35 94 °C / 1 minute
NCR4 35 55°C /I minute
Second round 35 70 °C/1 minutes
PCR 1 70°C/ 5 minutes
pause 10°C
Table 3.1 Summary of nested HCV PCR conditions used in first round
and second round amplification.
3.12 Single round PCR
The reaction mixture contained 0.5units of Taq DNA polymerase 
in 5jil of lOx (Tris/KCl) buffer supplied by the manufacturer; 2.5mM 
MgCh; 0.2mM each dGTP, dATP, dTTP, dCTP and 5 pmol of each pair of 
primers, #5 / #6, (table 3.2) in a final volume of 50|il. The reaction was 
over laid with 10(il of mineral oil to prevent evaporation and 2jnl of cDNA 
product was then added. Amplification conditions are summarised in 
Table 3.2. Analysis of the PCR product was performed as section 3.11.
The specificity of the amplification product was confirmed by 
Southern blotting analysis with a non-radioactive HCV probe.
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Primer
combination
Number of 
amplification cycles
PCR Temperature 
/Time
30 95 °C / 30 seconds
#5/#6 30 60°C /30 seconds
30 70 °C/1 minutes
pause 10°C/
Table 3.2 Summary of single round HCV PCR conditions used by Roche 
Discovery laboratory.
3.12.1 Southern blot analysis
Following electrophoresis the gel was soaked in denaturation solution for 30 
minutes, washed in distilled water, after which it was soaked in neutralisation 
solution for 30 minutes. The gel was then capillary blotted overnight using 6 X SSC 
onto Hybond N (+) membrane, which was presoaked in 6 X SSC. On completion of 
blotting the membrane was dried and the DNA was crosslinked to the membrane 
using a stratalinker (Stratagene). The membrane was prehybridised at 60 °C for 30 
minutes using 30ml prehybridisation mix containing: lOOjil 10% SDS; 0.5ml 20X 
Block solution (ECL kit); 2ml 50 X Denhardts solution; IO O jllI 10 mg/ml sheared 
salmon sperm DNA; and 5ml 10 X SSC in a final volume of 10ml. The denatured 
fluorescein-labeled probe was added to the prehybridisation mixture and allowed to 
hybridise overnight at 60°C.
The probe was made using the random prime ECL kit with the linearised 
plasmid (pBSK9 containing 5’UTR, Core, El and E2 regions of HCV (Nucleotides 
1-2545), using SP6 RNA polymerase, denatured for 5 minutes at 95°C and snap 
cooled for 2 minutes. The membrane was washed twice with two stringency washes: 
1XSSC, 0.1 SDS and 0.1%XSSC, 0.1% SDS and blocked with blocking solution 
(ECL kit) for one hour, followed by a 30 minute incubation with 20pl of a-
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fluorescein-HRP conjugated antibody (ECL kit). It was then wrapped in cling film 
with 20mls of detection mix (ECL kit) and exposed for autoradiography for 30 
minutes at room temperature.
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CHAPTER 4
Results and Discussion
4.1 Background
The severe combined immunodeficient (SCID) mouse is capable of accepting 
xenografts from a range of species including humans and has been used to 
develop a number of human mouse chimeras (Krensky, 1997).
The aim of this project was to establish a reliable animal model for hepatitis 
C virus (HCV) by using human hepatocyte SCDD chimera mice. The SCID human 
model for exoerythrocytic stages of Plasmodium falciparum was the basis for 
such a model (Sacci et al, 1992). Transplantation of human liver derived cell-lines 
or primary hepatocytes into SCID mice and infecting them either by in vitro or in 
vivo routes with HCV positive serum was the approach taken. The rationale rests 
on the hypothesis that these cells would attain a biologically functional state of 
differentiation in vivo, resulting in an increased sensitivity to HCV infection and 
acting as targets for HCV replication in an in vivo culture system. This would be 
assisted by a partial hepatectomy to stimulate primary hepatocyte proliferation 
(Michalopoulos, 1997). or inhibit excessive tumour development (Shiota et al, 
1996). Intrasplenic transplantation of hepatocytes would allow transplantation of 
large numbers of cells where translocation of these cells would be localised to the 
portal triad of the liver. Other sites of transplantation were both renal capsules. 
The animals would then be sacrificed at weekly intervals or after six weeks, and 
tested for HCV at these time points.
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There are a number of permissive liver derived cell-lines that have the 
potential for becoming infected with HCV under suitable in vitro culture 
conditions (chapter 1.2.1a). Of these, HepG2, Huh7 and WRL68 cell-lines were 
selected in addition to primary human hepatocytes taken from normal donors or 
HCV positive liver transplant recipients to develop this model. Tumour cell 
growth post-transplantation was verified histologically using haematoxylin and 
eosin (H&E) staining. Human albumin detection by in situ hybridisation and 
cytokeratin 18 staining with immunocytochemistry were used to confirm the 
presence of human derived liver cells after transplantation.
4.2 Preparation of cells for transplantation
To obtain a viable primary hepatocyte cell suspension, donor’s liver tissues 
(left lobe) were perfused with University of Wisconsin solution prior to 
transportation. Perfusion was performed within 24 hours from explantation, with 
4 different buffers (chapter 2.6.1).
Table 4.1 presents the viability of the primary hepatocytes prior to 
cryopreservation, estimated by trypan blue exclusion.
The number of cells obtained from cirrhotic HCV positive livers was reduced 
by one to two logs, however, their viability determined by trypan blue exclusion 
was relatively comparable to that obtained from normal livers. The tissue received 
from donor 4 was cirrhotic and difficult to perfuse. The low yield of cells from 
HCV positive donors could be attributed to cirrhosis of the tissue. This was also 
reported by Kusano et al, where the number of primary hepatocytes isolated from 
a cirrhotic liver was reduced with enzyme digestion perfusion method (Kusano et 
al, 1997). Cells isolated from donors 1, 2, 3 and 5 tested positive for HCV RT 
PCR and cytospin preparations of these cells were positive for human albumin 
expression.
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Donor
Donor
HCV
serology
Cell
Viability
(%)
Number of
cells
obtained
Method of 
freezing
1 Positive 92% lOVml NF
2 Positive 85% 10t,/ml NF
3 Positive 95% lOVml C.F
4 Positive
Not
Processed
Not
Processed
Not
Processed
5 Positive 87% 106/ml C.F
6 Negative 90% 108/ml C.F
7 Negative 98% 2.0xl0s/ml C.F
8 Negative 98% lOVml C.F
9
Not
done
99% 2.5xl07/ml C.F
Cell Freezer method: C.F 
Nalgene freezing box: NF.
Table 4.1 Perfused primary hepatocytes isolated from donor tissue, their 
viability, method of freezing and number of cells obtaine.
4.3 Surgery and Anaesthesia
In our hands a 40% hepatectomy had a perioperative mortality of 5% (9 of 192 
animals). This was comparable to Doer et aVs 4% mortality. Additionally, some 
animals died from anaesthetic exposure prior to surgery (2%), this was within the 
acceptable constraints of the animal project licence.
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4.4 Transplantation and engraftment
4.4.1 HepG2 cells
HepG2 cells are hepatoblastoma cells that secrete 17 of the major human 
plasma proteins into cell culture supernatant; these include albumin, 
alphafetoprotein and plasminogen. They resemble liver parenchymal cells 
morphologically and are chromosomally abnormal X  =55(50-56) with a 
distinctive rearrangement of chromosome 1 (Knowles et al, 1980).
A suspension of in vitro cultured HepG2 cells was either transplanted under 
the renal capsule and intrasplenically at a concentration of 106 cells per site or 
grown on inert silicon disks in vitro 3 days before transplantation. The disks were 
then implanted in the peritoneal cavity adjacent to the liver. The animals were 
inoculated with 50|il of (neat) HCV positive serum intraperitoneally (IP) one- 
week post transplantation. The results are presented in table 4.2 .
Transplantation
route
Number of
transplanted
animal
HCV
PCR
PHX
No
PHX
result
Spleen and
18 1 Negative
kidney
Disk 11 ND Negative
PHX: Partial hepatectomy ND: Not done
Table 4.2 Number of animals transplanted with HepG2 cells via two 
routes of cell transplantation and HCV RT PCR result.
Of the 33 transplanted animals (including 3 controls), 29 had a partial 
hepatectomy. None of the animals were transplanted with ex vivo infected HepG2 
cells. The controls for this experiment were two HepG2 transplanted animals
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injected IP with negative serum (one did not have a partial hepatectomy) and one 
animal implanted with a blank disk.
None of the RNA isolated from all the transplanted animals was HCV RT PCR 
positive. Overall HCV RT results will be discussed in detail in section 4.4 (a).
4.4.1(a) Pathology and histology
Of the 19 animals directly transplanted with HepG2 cells, 17 developed well- 
defined tumour masses demonstrated by H & E staining under the renal capsule. 
All animals developed tumors in the spleen with satellite tumors generated around 
vessels and under the capsule in the liver. These were vascular, encapsulated and 
often “lobated”. Some tumors were haemarhagic and necrotic, (figure 4.1a). The 
cells expressed albumin and were cytokeratin 18 positive; the former suggests that 
they had not dedifferentiated after transplantation, the latter indicating that they 
are epithelial in origin (figure 4.1b, 4.1c). The tumor cells resembled liver cells 
with prominent large nuclei that had a “ground glass” appearance. No metastasis 
was observed in the lungs or the myocardium in the transplanted animals; this is 
consistent with Victor et aVs observations in nude mice injected IP with HepG2 
cells (Victor et al, 1999).
Transplanted inert silicon disks containing HepG2 cells became vascularised 
and in some animals were attached to the liver mass. The tumor cells had 
infiltrated the disk crevices which in turn, became infiltrated with the animal’s 
fibrous tissue (figure 4. Id). However, HepG2 cells were not detected in any other 
tissue examined from these mice. None of the blank transplanted disks became 
vascularised and no mouse fibrous tissue was observed.
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Figure 4.1 HepG2 tumours in a transplanted SCID mouse
a) H&E staining o f  liver containing a tumour mass (T) with focal haemorrhage 
(x40 magnification).
b) Subcapsular renal tumour mass stained by albumin in situ hybridisation 
(xlOO magnification).
c) Subcapsular renal tumour mass stained by cytokeratin 18 immunocyto- 
chemistry (xlOO magnification).
d) H&E staining o f a silicon disk after implantation showing SCID fibrous 
tissue (F) and tumour infiltration (x200 magnification).
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4.4.3 WRL68 cells
The WRL68 cells are derived from human foetal, normal liver. They were 
registered as a patent (USA patent number 3 935066 in 1976) of human epithelial 
heteroploid liver cells by Apostolov (Apostolov 1976). The patent stated: “that 
these cells form individually separated islands on discrete clumps when cultured 
in growth medium they have a morphology closely resembling human 
hepatocytes and their generation time is no more than 24 hours. They also 
increase production of glycogen in the presence of 1 % glucose medium and could 
support viruses.” (Gutierrez-Ruiz, et al, 1994).
Gutierrez-Ruiz et al found that in vitro cultured WRL68 cells 
morphologically resemble hepatic primary cultures, secreting albumin and alpha- 
feto protein and preserving the activity of specific liver enzymes that include: 
alkaline phosphatase, gamma-glutamyl transpeptidase, aspartate amino transferase 
and alanine amino transferase (Gutierrez-Ruiz, et al, 1994).
The WRL68 cells used for transplantation were obtained from the European 
Collection of Animal Cell Cultures at passage number 92, stocks of this cell line 
were made and cryo-preserved. A suspension of these cells was transplanted intra- 
splenically and under the renal capsule at a concentration of 106 cells per site with 
or without performing a partial hepatectomy. Table 4.3 summarises the number of 
animals transplanted with WRL 68 cells, route of infection and RT-PCR results.
Of the 41 transplanted animals, 10 animals were transplanted with in vitro 
inoculated HCV cells and 22 animals were inoculated IP after transplantation. A 
partial hepatectomy was performed in 24 animals prior to transplantation. The RNA 
extracted from the spleen, kidney and liver was HCV RT-PCR negative.
4.4.3 (a) Pathology and histology
Gross post mortem examination of two animals of 39 one-week post 
transplantation revealed tumour dissemination throughout the peritoneal cavity, 
distributed on the surfaces of organs. This was more pronounced in animals that had 
not been hepatectomised. Microscopic examination of the myocardium from 3 of 39 
animals sacrificed 5 weeks post transplantation showed evidence of metastasis 
(figure 4.2 d).
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Infection
route
Number of animals
HCV PCR 
result
PHX No PHX
In vitro 5 5 Negative
IP 14 8 Negative
Uninfected
cells
5 4 Negative
PHX: Partial hepatectomy IP: intraperitoneal
Table 4.3 Number of animals transplanted with WRL68 cells,
route of infection and HCV RT PCR result.
Further, in most of the animals the tumour mass occupied around 20-30% of the 
spleen (figure 4.2 a) and 10-20% of the kidney (figure 4.2 b), spreading internally 
from the sup-capsular space. In the liver, the tumours were encapsulated with 
several satellite tumours (figure 4.2 c). The animals had swollen abdomens and 
were sacrificed before the final experimental time point (six weeks).
Tumours in all transplanted animals expressed cytokeratin 18, but failed to 
express human albumin or alpha-fetoprotein. Similarly, cytospin preparations 
made from WRL68 cell suspensions did not stain for human albumin. The latter 
contradicts Gutierrez-Ruiz, et aVs observations (Gutierrez-Ruiz, et al 1994). It is 
possible that our cells derived from a higher cell passage had become 
dedifferentiated; alternatively, our cells expressed these proteins in minute 
amounts and as a result were not detected.
Histologically, the tumour cells had a polygonal to spindle arrangement, 
exhibiting prominent round or oval nuclei. In some cells the cytoplasm appeared 
granular and dense.
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Figure 4.2 WRL tumours in a transplanted SCID mouse
a) H&E staining o f WRL tumour spreading beneath the 
renal capsule (xlOO magnification).
b) H&E staining o f a spleen with a large tumour 
(x40 magnification).
c) Two WRL tumours in the liver (x40 magnification).
d) WRL tumour metastasis in the myocardium (x40 magnification).
T : WRL tumour
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4.4.4 Huh7 cells
The Huh7 cell-line was established from well-differentiated hepatocellular 
carcinoma tissue. The cells express a number of plasma proteins in vitro, 
including alphafetoprotein and albumin (Nakabayashi et al, 1982). When 
transplanted into nude mice through the portal vein, liver metastases were present 
in 80% of the animals (Shiota et al, 1996).
A suspension of these cells was transplanted intrasplenically and under the 
renal capsule at a concentration of 106 cells per site with or without performing a 
partial hepatectomy. However, no infection experiments were performed because 
the animals became unwell. Of the 20 animals transplanted 11 were sacrificed one 
week posttransplantation and the remaining animals were sacrificed 10 days post­
transplantation.
4.4.4 (a) Pathology and histology
The development of extremely large haemorrhagic tumours in the abdominal 
cavity was substantiated by gross postmortem examination of the animals. 
Microscopic examination of these tumour masses revealed large vascular, 
encapsulated tumours, which were haemarrhagic with extensive necrosis (figures 
4.2 a, 4.2 b) occupying 50% of the organs examined, with a large number of 
mitotic figures. No metastasis was observed in the lungs or the myocardium. The 
cells resemble liver parenchymal cells morphologically with large prominent 
nuclei; they also expressed human albumin and cytokeratin 18.
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Figure 4.3 Huh7 tumours in a transplanted SCID mouse
a) H&E staining o f a SCID kidney with large haemorrhagic and 
necrotic tumours (to the left o f the figure)
(x40 magnification).
b) H&E staining of a SCID liver w ith 2 large tumours 
(x 40 magnification).
T: Huh7 tumour
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4.4.5 Primary hepatocytes
Hepatocytes are anchorage dependent cells, which are structurally and 
functionally polarized in vivo. When cultured on plastic, they attach poorly with a 
gradual loss of hepatocyte specific functions, such as albumin synthesis, and as a 
consequence soon die. Provision of an extracellular matrix would allow prolonged 
survival, continued expression of differentiated functions and preservation of a 
more normal, near-cuboidal cell shape. This could be achieved by transplantation 
of primary hepatocytes within the liver extracellular matrix, which intervenes 
between fenestrated endothelial cells and hepatocyte epithelium, thus allowing 
interaction between transplanted hepatocytes and non-parenchymal cells for 
example Kuppfer cells. A progressive decrease of albumin production in vitro in 
pure populations of hepatocytes has been observed; however, when co-cultured 
with endothelial cells, albumin production was maintained (Morin and Normand, 
1986).
Syngeneic and allogeneic transplantation of primary hepatocytes in rodents 
has been successful. For example, syngeneic transplanted primary hepatocytes 
can survive up to 2 years in the spleen of a rat (Sawa, 1997). In the malaria mouse 
model, primary human hepatocytes can become infected with sporozoites of 
Plasmodium falciparum 4 months after transplantation (Sacci et al, 1992).
Hepatocytes used for transplantation were either from HCV positive donors 
or from normal donors. The spleen and renal capsules allow the transplantation of 
a large number of cells; this increases the chances of engraftment. The short-term 
elevation of hepatocyte growth hormone levels after a partial hepatectomy allows 
initial cell proliferation (Michalopoulos, 1997).
Perfused cells from donor 1 were cryo-preserved using a Nalgene freezing 
box. Their viability was comparable to that obtained after perfusion (90%). Cells 
obtained from donor 2 were transplanted within one hour after perfusion. All 
animals were partially hepatectomised prior to transplantation. The animals were 
sacrificed 6 weeks post transplantation; RNA was extracted from whole blood, 
and samples taken from the spleen, liver and kidney. The remaining tissues from
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these organs were processed for human albumin, cytokeratin 18 and H & E 
staining.
Table 4.4 outlines the number of animals transplanted with HCV positive 
hepatocytes obtained from donors 1 and 2:
Donor No
No of 
transplanted 
animals
Histology
results
HCV PCR 
results
1 6 Negative Negative
2 4 Negative Negative
Table 4.4 Number (No) of animals transplanted with fresh HCV donor 
hepatocytes, or with cryo-preserved hepatocytes
No cells were detected in the spleen or the renal capsules in all animals 
examined and no HCV was detected. As a result, it was decided to transplant 
fresh hepatocytes after perfusion (up to 20 hours post perfusion) and sacrifice the 
animals at weekly intervals. Further, primary HCV negative hepatocytes would be 
transplanted after ex vivo infection with HCV positive serum (Roche Discovery), 
or after mixing with HCV negative serum. Two further animals transplanted with 
cells from donor 7were not hepatectomised; the cells were either treated with 
negative or positive HCV serum. The effects of mixing with freezing medium and 
storing for 10 hours at 4 °C post-transfusion on cell viability was tested by 
transplantation of hepatocytes from donor 8. The remaining perfused cells were 
cryo-preserved using a cell freezer.
Table 4.5 summarises the number of animals transplanted with freshly 
perfused HCV negative primary hepatocytes obtained from donors 6,7, and 8.
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CHAPTER 4 Results & Discussion
No primary hepatocytes were detected in these animals from all donor livers 
and HCV PCR results were negative.
Fresh HCV positive primary hepatocytes were transplanted either at 3 or 24 
hours post perfusion, and all the animals were hepatectomised (Table 4.6).
RNA was extracted from whole blood, and samples from the spleen, liver and 
kidney, were then sent to Roche laboratories for HCV RT-PCR testing (discussed 
in section 4.4 b). The remaining tissues from these organs were presented for H & 
E, human albumin and cytokeratin 18 staining.
4.4.6 Cause of primary hepatocyte absence
The absence of primary hepatocytes in the spleen or under the renal 
capsule, one week post transplantation was investigated by addressing the 
following possibilities:
4.4.6 a) Needle size and its effects on cell viability
The question arose as to whether the gauge of the needle may be 
damaging the cells, thus leading to cell lysis during the transplantation procedure. 
A needle size of 27G had previously been used in the successful transplantation of 
WRL-68 and HepG2 cells; using larger gauge (> 25G) needles could be 
considered unacceptable as it could lead to excessive bleeding in the mouse.
An in vitro experiment to address this phenomenon was undertaken, where frozen 
aliquots of primary hepatocytes from donor 7 were thawed; their viability was 
>90%. Cells were passed through 27G, 25G and 23G needles (27G < 25G < 23G), 
incubated at 37°C in PBS and their viability tested again at times 0, 1 hour and 3 
hours. Results summarized in Tables 4.7a, 4.7b and 4.7c
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Figure 4.4 Primary hepatocytes one hour posttransplantation in 
a SCID mouse spleen.
a) Transplanted primary hepatocytes (phhc) stained by 
cytokeratin 18 immunocytochemistry (x200 
magnification).
b) Transplanted primary hepatocytes stained by albumin 
in situ hybridisation (xlOO magnification).
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Sample Treatment with 
needle
Cell
Number/50jil
% Viability
Control (no treatment) 3.8xl05 87
27G 2.2x10s 82
25G 2.2xl05 90
23G 2.2x10s 89
Table 4.7 (a) Viability of primary hepatocytes at time 0 after treating
the cells with different size needles
Sample Treatment 
with needle
Cell Number/50|il % Viability
Control (no treatment) 4 . 0 x l 0 5 91
27G 2 .5 X 1 0 3 61
25G 2 . 8 x l 0 5 92
23G 2 . 7 x l 0 5 92
Table 4.7 (b) Viability of primary hepatocytes after 1 hour
Sample Treatment 
with needle
Cell Number/50jjl % Viability
Control (no 
treatment) 2.4x105 88
27G 0.9x10s 66
25G 2.0xl05 87
23G 2.3x10s 81
Table 4.7 (c) Viability o ‘ primary hepatocytes after 3 hours
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All the cells had a comparable viability after passing them through the different 
needles prior to incubation, however, the viability of cells treated with needle size of 
27G was reduced to 61% one hour post-incubation, suggesting possible cell lysis. 
After 3 hour incubation all the cell viabilities remained relatively comparable to 
those after one hour incubation.
To assess the cell’s response to different needle gauges in vivo an experiment was 
also undertaken where cryo-preserved HepG2 and cryo-preserved hepatocytes from 
donor 7 were transplanted in 5 mice, using 27G (only used in one animal), 25G or 
23G needles. The mice were sacrificed 1 hour after surgery. Tissues were stained for 
H & E, albumin and cytokeratin 18.
The transplanted primary hepatocytes were only detected in the spleens of each 
animal by cytokeratin 18 and albumin staining (Figures 4.4 a and 4.4 b); irrespective 
of the needle used. Staining of the kidneys for albumin and cytokeratin 18 was 
negative. It is possible that some of the transplanted hepatocytes might have leached 
out during transplantation under the renal capsule. Both the spleen and kidneys 
stained positive for albumin and cytokeratin 18 in the mice transplanted with HepG2 
cells; the 23G needle was not used to transplant HepG2 cells.
4.4.6 b) Transport medium: PBS versus medium.
Hepatocytes are metabolically active cells that require growth factors and 
hormones to survive. Epidermal growth factor (EGF) has wide ranging mitogenic 
activities on cells in culture. Richman et al were the first to show that EGF, 
especially in combination with insulin and glucagon, could stimulate DNA synthesis 
in isolated hepatocytes maintained in monolayer culture (Richman et al,. 1976).
As all cells had previously been transported in PBS and the surgery can take up to 
4 hours, we decided to test whether medium (DMEM, 1%, Bovine serum albumin 
0.02|ig/ml Epidermal growth factor, lOU/ml Insulin) rather than PBS would better 
sustain the cells prior to transplantation. Cryo-preserved cells from HCV negative 
donors were suspended in medium or PBS and incubated for 5 hours at 37°C (Table 
4.8). The cell viability was reduced in the presence of PBS after a 5 hour incubation.
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Primary hepatocyte 
source
% Cell viability in
PBS medium
donor 6 27 >90
donor 9 40 >90
donor 7 0 88
donor 8 0 86
Table 4.8 Viability of different Primary hepatocytes suspended in either
PBS or medium after a 5 hour incubation
4.4.6 c) Survival of cryo-preserved primary hepatocyytes in vivo.
To investigate the influence of transport medium on in vivo survival time, 8 
mice were transplanted with primary hepatocytes from donor 9 using a 25G needle. 
They were sacrificed at 1, 3, 24, 48 hours and 1-week intervals; the spleen, liver and 
kidneys were stained for cytokeratin 18 and human albumin, results are summarized 
in Table 4.9
Cells from animals sacrificed one and three hour post transplantation were 
positive for albumin and cytokeratin 18 staining in both kidneys. Cells from animals 
sacrificed one hour post transplantation were also detected in the spleen. However, in 
animals sacrificed at 24, and 48 hour post transplantation, primary hepatocytes only 
stained for cytokeratin 18 in the kidney (Figure 4.5). The absence of cells in the 
spleen could be due to the cells being translocated to the liver. The lack of albumin 
staining could either be attributed to the fact that the cells are in an acute phase 
response resulting in down regulation of albumin production (Selden et al, 1999), or 
that mRNA has degraded because the cells are dying. Cytokeratin 18 stain is more 
robust than albumin as it is a cytoskeletal stain, explaining it’s detection at 48 hours 
posttransplantation. However, no primary human hepatocytes were detected in the 
animals sacrificed at one-week.
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Figure 4.5 Primary hepatocytes 48 hours post 
transplantation in a SCID mouse
Cytokeratin 18 immunocytochemistiy o f 
primary hepatocytes (phhc) transplanted in the 
kidney subcapsule (x200 magnification).
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To test the survival rate of cryo-preserved hepatocytes obtained from different 
donors (5, 6 and 7,) a similar experiment was conducted using 8 animals, the 
animals were sacrificed at 1, 3, 24, 48 hours 4 and 6 day intervals.
Similar results to those above were observed in animals transplanted with cells 
from donor 7.Surprisingly, animals transplanted with cells from donors 5 and 6 
were negative for both albumin and cytokeratin 18, suggesting that these cell’s 
viability was somehow compromised after transplantation
4.4.6 d) In vivo survival of transplanted human hepatocytes after 
macrophage depletion
Macrophages have been implicated as the main effector cells, as judged by 
F4/80 immunocytochemistry, in xenograft rejection of porcine islet cell clusters 
after transplantation under the kidney capsule of normal C57BL6mice (Karlsson- 
Parra et al 1996). Lin et al elucidated the pathogenesis of delayed xenograft 
rejection in the transplantation of hamster heart to leflunomide-treated rats and 
attributed to macrophage activation by xenoantigens in the absence of NK cells 
and xeno-antibodies (Lin et al 1997). Further, previous unpuplished data have 
indicated that primary foetal hepatocytes are destroyed by macrophages in nude 
mice (personal communication, F. Prince, the Lindsley F. Kimball research of 
New York Blood Centre). Thus, macrophage ablation may enhance the survival 
of primary human hepatocytes in this model.
Macrophage depletion with the purpose of facilitating engraftment of 
allogeneic and xenogeneic bone marrow grafts has been demonstrated with silica 
(Lotzova et al. 1974), where silica abrogates or weakens resistance to parental, 
allogeneic and rat marrow grafts. Recently, in vivo macrophage depletion has 
been achieved by the administration of liposomes containing dichloromethylene 
diphosphate (DMDP). Such liposomes are injested by macrophages and after 
dismption, their contents will kill these cells effectively. The route of 
administration of the liposomes will determine the population of macrophages
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removed; for example: intravenous injection mainly eliminates phagocytic cells in 
the spleen and the liver (Terpstra et al, 1997).
DMDP is more effective than silica, which does not appear to completely 
eliminate the macrophages. Unfortunately, it is highly toxic to the mice, so 
increasing the severity band of the project license. Therefore macrophage 
depletion by DMDP was not attempted.
To test the effectiveness of silica, 8 animals were used and treated with or 
without silica. After partial hepatectomy and transplantation of cryo-preserved 
primary hepatocytes (donor 8), 0.2ml (38.5mg/ml) of silica was administered to 
the peritoneal cavity of a group of 4 mice. To compare its effect, a control group 
of 4 untreated mice was sacrificed concurrently at 24, 48 (one mouse from each 
group at each time point) and remaining two mice from each group, 72 hour 
intervals post-transplantation. Tissues were stained for H & E, albumin and 
cytokeratin 18; and to detect the presence of macrophages, the F4/80 antibody 
was used.
Surprisingly, no primary hepatocytes were detected in both groups at 24 
hours post transplantation, as determined by albumin and cytokeratin staining. 
However, gross examination of the abdominal organs showed thickening of the 
capsular wall compared to normal mice. This was confirmed microscopically, 
with H&E staining showing “thickening” of the capsular membrane in the spleen 
and kidney in the silica treated animals indicating a possible inflammatory 
response to the silica (figures 4.6a, 4.6b).
The F4/80 antibody staining, which will identify red pulp macrophages 
(Austyn and Gordon 1981), is demonstrated in normal mouse spleen (Figure 4.7a) 
and SCID mouse spleen (Figure 4.7b). In the animals treated with silica and 
sacrificed 24 and 36 hours post transplantation there was substantial abolition of 
macrophages in the spleen (4.7c). However, after 72 hours, the macrophages 
reappeared (4.7d). The application of silica therefore did not affect the 
unsuccessful outcome of transplantation of primary hepatocytes from donor 8.
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aFigure 4.6 "Thickening” of the capsular membranes of spleen and 
kidney post silica treatment of a transplanted SCID mouse
a) H&E staining of a spleen from a SCID mouse treated with silica 
(xlOO magnification).
b) H&E staining of a kidney from a SCID mouse treated with silica 
(x200 magnification).
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4.4.6 e) Growth stimulants: priming before implantation
The rationale for performing a partial hepatectomy was to stimulate liver 
regeneration in the mouse thus releasing active hepatocyte growth factor (HGF) 
and other mitogens including interleukin-6 (IL6) (chapter 1.3), into the blood 
stream and stimulating DNA synthesis in the transplanted hepatocytes by binding 
to the c-met receptor. This in turn would allow the transplanted cells to become 
established. However, the question arose as to whether there were sufficient 
growth stimulants to sustain the transplanted primary hepatocytes and maintain 
them in a biologically functional state of differentiation.
The administration of recombinant HGF by IP injection could resolve this 
problem, but it would be too costly, in the region of £ 1000/mouse.
The use of an agonist against c-met receptor that will activate it and evoke 
DNA synthesis and cell proliferation is another approach. Prat et al demonstrated 
agonistic activities of monoclonal antibodies against the extracellular domain of 
HGF-R {c-met) triggering biological responses required for invasive growth (Prat 
et al. 1998). They postulated that ligand-induced oligomerisation was the most 
likely mechanism responsible for activation of growth factor receptors (Prat et al. 
1998).
An antibody that had been raised against human HGF-R, which does not cross 
react with mouse HGF-R, which would preferentially stimulate the transplanted 
primary human hepatocytes was made available by Dr Ken Hillan from 
Genentech, Inc.,South San Francisco, California, to test in this model. 50jig of 
anti-met antibody was mixed with 3x10 6 cells from donor 8 prior to 
transplantation and a group of 8 mice were sacrificed at intervals of 3, 6, 10 days, 
3, 4 and 5 weeks; (Table 4.10).
Unfortunately, no primary hepatocytes were detected in all the transplanted 
animals. This could be attributed to lack of binding of the antibody to donor 8 
cells, or that the animals macrophages prevented engraftment.
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No. of 
animals
Time of 
sacrifice
Albumin
(ISH)
Cytokeratin 18 
(ICC)
2 3 days Negative Negative
2 6 days Negative Negative
2 10 days Negative Negative
2 3 weeks Negative Negative
2 4 weeks Negative Negative
2 5 weeks Negative Negative
ISH In situ hybridisation
ICC imunocytochemistry 
Table.4.10 Summary of the effects anti -met antibody in SCIDS
Priming the cells with interleukin-6 (IL6) in the presence of EGF prior to 
transplantation, and combining this with the anti-met antibody, was another 
approach adopted, for IL6 results in hepatocyte proliferation in vitro (Kuma et al 
1990), and might encourage cell proliferation prior to transplantation. To address 
the possibility of macrophage inhibition, silica was used during transplantation. 
Using a 25G needle and in the presence of DMEM with EGF (0.02|Lig/ml), 
primary hepatocytes from donor 7 were mixed with either anti-mef antibody, IL6 
(1000 U/107cells) or silica; the animals were sacrificed at either 5 or 10 day 
intervals (Table 4.11). However, despite of the use of silica no hepatocytes were 
detected in the transplanted animals.
ft
GG
g
g (D D d> a>
. 2  w> > > > >8 3 c • ^ » »H »tpHH .S3^ ^ «H ed G ed Cj2  s  .S bX) bJQ bX) bX)>> ft  Cd 1) D <L> <D
U  3  tA z Z Z £
C4-h
o  .8
D Jtn G *-« ^
©  l—H oc  o  >p 
r~* G G 3E”"1 CA ft »r» vn IT) <o
>>
f t f t f t
O O O
G
D
f t» y»H r\ w f t  .O ft
G G _ G f t GG
ed
ed G cJ 3  CA-t—< G 25*<U f—H G 3t-i
H
• ^C/3•*-* _* o** f t G*>» O
o
^  “ cu .td CU f t
? u ¥ ^ ? ^ £
f t  vo ft  vo •ft ft ft
§  d 1  d S § §
ft
G
<* 2O bX)
<3 3s
X) G 
G GG G 
^ '3 
£  § <N CS -
vo
c
22
gu
i - t<D
VO
d
QHH
U
CZJ
#g
GU
O
VVcs4>
ca4»G
f t
0>J3
C• p4
f t  
°  2-° sft Of tCa g
i  £
, i  CAft w 
c
C3 
f ta a 
ve
>» w O
G 
&
a ■?
2  gs £
f t
f tCAa
g
tt
3
03
H
CHAPTER 4 Results & Discussion
4.5 RNA and RT-PCR analysis
4.5.1 Nested RT PCR
For consistency, Chomczynski and Sacchi’s method for RNA extraction 
was used (Chomczynski and Sacchi, 1987), on all samples. The RNA of tissue 
samples was quantified spectro-photometrically and ljLLg was used to synthesise 
HCV cDNA with the Vtaq primer for the 5’UTR region; but for 200|il serum/ 
plasma samples, 3 |il of extracted RNA was used. The 5’UTR region was chosen 
because it is highly conserved among different HCV isolates (Smith et al 1995). 
To test the sensitivity of the extraction and nested RT PCR methods, the Pelispy 
HCV-RNA run control at two dilutions, 1/5 and 1/10 were used. The Pelispy 
sample, is a weak positive plasma standard for the validation of HCV-RNA 
amplification test runs. It contains 3800 genome equivalents /ml and was obtained 
from Central Laboratories of the Netherlands Red Cross Blood Transfusion 
service. Alternatively, HCV positive serum at a 10-4 dilution was used. 
Additionally, RNA was extracted from 10 6 primary HCV positive hepatocytes 
with each extraction run. Figure 4.8 is an example of a typical RT PCR run. All 
SCID tissue RNA was negative, both the Pelispy dilutions were positive; thus the 
sensitivity of the nested PCR run was around 100 genome equivalents per 
reaction.
4.5.2 Single round PCR
This was performed as part of a collaboration with Roche Discovery 
Laboratories, Welwynn Garden City (Adina Ochert) RNA samples from 
experiments in section 4.3 were tested. Extraction controls were included; an 
RNA sample from 106 HCV positive primary hepatocytes and an HCV positive 
serum (104 dilution). The sensitivity of this method was around 200 genome 
equivalents/ reaction as estimated by titration of plasmid RNA. However, only 3 
of the 10 positive controls were positive, suggesting that the results were at the 
limits of this method’s detection.
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Since there was no evidence of human material transplanted in the SCID 
mice, the PCR data are in accordance with the histology data.
4.6 Summary of results
The liver derived cell lines used in this model were successfully transplanted in 
SCIDs with out the loss of albumin production, and by inference loss of 
differentiation. However, these cells have several drawbacks, for some produce 
extremly large metastatic tumours that are hemorrhagic resulting in the animals 
death. Inhibition of these tumours by the production of HGF as a result of a partial 
hepatectomy was ineffectual. Allied to this, these cells were not susceptible to 
HCV infection in an in vivo culture system, irrespective of the route of infection, 
viral titre (107 genome equivalents/ ml of serum) and source of the infectious 
serum. Consequently, they are not suitable candidates for the production a HCV 
animal model. Using inert silicon disks as a means of introducing cells in vivo, in 
theory, offers an alternative replacement. For, in this model these disks became 
vascularised with infiltration of host fibrous tissue. But the cell’s proliferation was 
not as pronounced as direct cell transplantation over the experimental time scale. 
As a consequence this was not a realistic substitute. Primary human hepatocytes 
(PHHC) did not successfully engraft after transplantation. To date PHHCs were 
not detected one week post transplantation however, similar results have recently 
been demonstrated in nude mice by Kusano et al (Kusano et al, 1997). Unlike the 
malaria mouse model (Sacci et al, 1992), PHHCs survive for only 48 hours post 
transplantation as was demonstrated by cytokeratin 18 staining. Results from the 
anti -met antibody, EL6 and silica experiments should in theory demonstrate an 
increase in the survivability and proliferation of the PHHCs in vivo, but this was 
not the case. It is possible that the perfusion and freezing processes might have 
some how compromised the cells. Alternatively, the animal’s NK cells may have 
destroyed the cells after transplantation.
92
CHAPTER 5 General discussion
CHAPTER 5 
General Discussion
The difficulties associated with establishing an in vivo HCV model are, to 
a certain extent, linked to the availability of a reliable source of cells that would 
support HCV replication. In vivo transplantation of hepatocyte derived cells may 
allow them to attain a “biologically functional” state of differentiation, increasing 
their susceptibility to HCV. Ideally, a non-metastatic cell-line with attributes 
comparable to primary hepatocytes should be used. This could be achieved by, for 
example, simian virus 40 (SV40) transformation (Nakamura et al 1997). The 
absence of a cheap and accessible HCV animal model, and the lack of a suitable 
in vitro repeatable culture system are reasons for attempting this project.
Several approaches were attempted at developing an animal model for HCV. The 
following could explain the unsuccessful outcome of this project:
5.1 Serum infectivity and hepatocyte derived cell susceptibility in vivo
The absence an HCV PCR signal in transplanted animals could partly be 
attributed to a low viral titre or a lack of infectious virus in the inoculum. But the 
sera used in this model were from two HCV RNA positive patients, one of whom, 
had chronic HCV, the other was a Sacramento blood donor with cryoglobulinemia 
/ macronodular liver disease. The latter also had a titre of 107 genome equivalents 
/ml of serum and produced a positive strand HCV RNA signal after in vitro 
inoculation of Huh7 and WRL68 cells and for the duration of 4 weeks (personal 
communication, Adina Ochert, Roche Discovery, Welwyn Garden City). 
However, negative strand RT PCR was not performed on these cultured cells or 
supernatant to confirm viral replication.
Non-infectivity of RNA positive sera has been previously reported. 
Lanford et al screened a number of sera from chronically infected individuals,
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using chimpanzee primary hepatocytes and found many non-infectious. Further, 
their infectivity did not correlate with PCR titres (Lanford et al, 1994). Similarly, 
Fournier et al detected both negative and positive strand HCV RNA in 10 of 33 
primary hepatocyte cultures infected with 33 different HCV positive sera. They 
also noted a high titre in the inoculum is necessary but not sufficient for in vitro 
infection of primary hepatocytes (Fournier et al, 1998). Rumin et al (1999) 
reported that different virus variants can replicate in primary hepatocytes 
irrespective of the viral titre, but sera displaying low anti-E2 antibodies or no 
neutralisation of binding titres may be more infectious in vitro (Rumin et al, 
1999). Therefore, the presence of neutralising antibodies to specific domains in 
the viral envelope region could abrogate the infectivity of an inoculum and may 
explain this anomaly. Alternatively, the sera may have contained lymphotropic 
HCV isolates. Tropism to lymphocytes though controversial, has been reported 
(Chapter 1.2.1), and might explain the absence of infectivity of the two sera used 
in this animal model.
Intrinsic resistance to HCV infection of the transplanted cells could also 
explain the absence HCV replication. HCV replication was only achieved in the 
presence of DMSO or and normal human serum, both favouring long-tem 
maintenance of highly differentiated hepatocytes (Rumin et al, 1999). Virus 
attachment and subsequent replication might be dependent on the cellular 
replicative cycle. For example, reovirus infection of murine hepatocarcinoma 
cells in vivo is correlated with cellular division, as virus antigen is only present in 
dividing cells (Taterka et al, 1994). On the other hand hepatitis B virus replication 
in transfected hepatoblastoma cells, is enhanced in quiescent hepatocytes (Ozer et 
al, 1995). The transplanted hepatocyte derived cells in this model metastasised 
and did not support HCV. It is possible therefore, that HCV will only attach and 
replicate in quiescent cells. However, HCV core protein localization in the 
cytoplasm of transfected HepG2 cells, is not cell cycle dependent (Barba et al, 
1997). Ideally a panel of HCV positive sera should have been tested for the 
production of negative strand HCV RNA on the selected cell-lines in an in vitro 
culture system. This was not attempted. Further, these cells could behave
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differently in vivo, de-differentiating and losing their ability to sustain HCV. The 
expression of the albumin gene mRNA, a liver specific marker of functional 
activity and differentiation, was sustained in for example the HepG2 cells after 
transplantation, but this is only one gene of a potentially large number confirming 
liver specific activities. Because CD81 has been implicated as the site of HCV 
binding, the lack of expression for this possible HCV receptor on the tumour cells 
in vivo, might also explain the lack of a PCR signal. Interestingly, the cell-line 
Huh7 expresses CD 81 receptor while the cell-line HepG2 lacks the expression of 
this receptor in vitro (personal communication from Dr Arvin Patel at the Institute 
of Virology, MRC Virology Unit, Glasgow 1999).
5.2 In vivo primary hepatocyte viability and engraftment
Albumin expression mRNA in sequential histological sections from the 
transplanted animals was used to establish cell viability and successful 
engraftment in this model. However, perfusing primary hepatocytes and 
separating them from the cell matrix could lead to an acute phase response, 
resulting in down regulation of albumin production (Selden et al, 1999) and might 
explain the loss of the albumin signal in vivo as early as 24 hours post­
transplantation (Chapter 4.35 c). Cytokeratin 18 staining was used to confirm the 
presence of primary hepatocytes and display their morphology. However, a more 
precise measurement of hepatocyte viability, in vivo and after cryo-preservation 
was warranted.
One approach could involve testing the maintenance of the hepatocyte 
enzyme system, cytochromes P450, which serve as electron acceptors and mono­
oxygenases in electron transport systems (Wang et al 1997). This could be 
performed on in vivo extracted mouse RNA samples using an RT-PCR method to 
test the mRNA for three P450 cytochrome enzymes: 2E1, 1A2 and 3A4 
(Finnstrom et al 1999). This could also be used on the cryo-preserved hepatocyte 
batches, retrospectively acting as a back up for the trypan blue exclusion test and 
as a result might help define the reasons for the absence of cells 72 hours post­
transplantation. An initial selection on the basis of viability could be performed
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prior to transplantation, allowing transplantation of robust cells. Confirmation of 
retrospective successful engraftment of transplanted cells can also be achieved 
with PCR amplification of human Alu Sb2-containing loci using primers R16A/6 
corresponding to the 5’ end of the Alu consensus sequence and the INS2 Sb2 
specific oligonucliotide primer (Ziekiewicz et al, 1994).
5.3 Possible mechanisms of primary hepatocyte rejection in this model
The maximum survival time of primary hepatocytes in this model was 
limited to 72 hours post-transplantation; this was irrespective of the pre-treatment 
of the cells prior to transplantation (Chapter 4.3.5). Similar results have recently 
been demonstrated in nude mice by Kusano et al suggesting a reduction in growth 
factor production especially, hepatocyte growth factor 72 hours post partial 
hepatectomy (Kusano et al. 1997), (Chapter 1.3). The use of albumin-urokinase 
(Alb Upa) transgenic mice, in which a fuctional liver deficit created by 
hepatocyte-targeted expression of a hepatotoxic transgene, and results in a chronic 
stimulus for liver growth, was, explored (Rhim et al 1994). But most Alb Upa 
colonies are infected with Helicobacter hepaticus (personal communication from 
Mr Colin Hughes, Biological services, University of Glasgow), which is a 
naturally occurring pathogen causing chronic hepatitis and liver cancer (Ihrig et al 
1999).
Treatment of the animals with silica to nullify or weaken the impact of the 
mouse’s macrophage cells, though successful was ineffectual in our model in 
protecting transplanted human hepatocytes.
Peripheral natural killer (NK) cells have been implicated in marrow 
allograft rejection in SCID mice (Murphy et al. 1987) .The fact that liver NK 
effector cell functions become temporarily suppressed during liver regeneration 
will, in theory, protect regenerating hepatocytes (Vujanovic et al. 1995) but only 
in the liver. Since the sites of transplantation were the spleen and the renal 
capsules, it is possible that peripheral NK cells could have contributed to the 
primary hepatocyte lysis; via apoptosis and primary necrosis in vitro. Interleukin 
-2  activated rat NK cells were shown to be fully equipped to induce both
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apoptosis and necrosis in primary hepatocyte (Blom et al, 1999). In vivo depletion 
of NK cells by anti-NKR-Pl monoclonal antibody could remove these cells 
augmenting liver regeneration following a partial hepatectomy (Vujanovic et a l
1995). Alternatively, SCID/Beige mice could have been used for these animals 
intrinsically have low NK cell activity (Mosier et al, 1993). The latter approach 
was not pursued, as it was difficult to obtain these animals in the time constraints 
of the project.
One other explanation for hepatocyte rejection was that host granulocytes 
lyse the cells after transplantation. Olszewski et al found host granulocytes 
responsible for the rapid destruction of transplanted hepatocytes in syngeneic and 
allogeneic recipient rats. As granulocytes were found surrounding intra- 
peritoneally infused hepatocytes after 2 hours, where the hepatocytes had a 
pyknotic appearance; 24 hours later all the hepatocytes were lysed. A similar 
reaction was observed in subcutaneously transplanted hepatocytes. Additionally, 
granulocytes were found to be cytotoxic to hepatocytes in vitro (Olszewski et al,
1996). This could offer a plausible explanation for the rapid disappearance of the 
transplanted hepatocytes in our model, as Olszewski et al postulated that isolating 
cells from a solid organ, like the liver, might damage their membrane during the 
isolation procedure. This in turn and the release of intracellular chemical 
substances could act as a “chemo-attractant”, mobilizing the host granulocytes 
(Olszewski et al, 1998). Circumvention of transplanted primary hepatocytes from 
the animal’s immune system is therefore essential to allow prolonged survival of 
these transplanted cells.
Encapsulation of these cells in semi-permeable membranes is one 
approach, for it allows isolation from the host’s immune system while permitting 
metabolic exchanges. This has been demonstrated by Wen et al where human 
hepatocytes were encapsulated in semi-permeable hydrogel based hollow fibres 
and implanted in the peritoneal cavity of Lewis rats. Human albumin presence 
was demonstrated in rat sera as assessed by Western blot and by ELISA. 
Immuno histochemical staining for albumin of the encapsulated cells was also 
demonstrated after 28 days (Wen et al, 1998). Micro-encapsulation of hepatocyte
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derived cell-lines could also protect the host from the metastatic attributes of 
these cells. This is one approach that has not been attempted in SCID mice and 
might be a valuable tool for the development of a HCV animal model.
To date there has not been a successful SCID/ human chimeric HCV 
animal model developed using either PHHC or hepatocyte derived cell line’s 
transplantation techniques. However, Ohashi et al recently demonstrated the 
successful transplantation and subsequent infection of human primary hepatocytes 
in non-obese diabetic (NOD)/ SCID mice with HBV and hepatitis delta virus 
(HDV). The hepatocytes were transplanted in a matrix (matrigel), under the 
kidney capsule and an agonistic antibody against c-met was administrated IV 
every 2 weeks. The cells were infused with 108 HBV genome equivalents by 
injection of equal amounts into the transplant and intravenously. HBV infection 
was demonstrated by Southern blot analysis of HVB DNA replicative forms, 
immunohistochemical staining for HBsAg and HBcAg of the transplanted cells 
and by serial inoculation of other transplanted mice after 10 weeks from the 
original inoculation. Immunohistological examination of these samples showed 
both HBsAg and HBcAg positive staining. Superinfection with HDV was 
achieved by infecting with HBV and injecting them 60 days later with HDV 
positive serum. HDV RNA became detectable in the serum 10 days post infection 
and remained so for 4 weeks.
Ohashi et a l’s approach differed from this project’s in that the transplanted 
hepatocytes were supported by a matrix and the agonistic antibody was 
administered IV at weekly intervals with out the performance of a partial 
hepatectomy. Thus, the hepatocytes were stimulated continually and as a result 
would have retained their differentiated state, allowing their infection by these 
viruses. Ohashi et aVs approach therefore has potential for the development of a 
HCV animal model.
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Appendix I
Appendix I
Shower area
Category 3 Containment-room
SG-PI SG-PJSink
Sink & draining 
board
Ante-room Fridge
Class II MSC
SG-AI
NPI
PPI
Outline of the Category III laboratory
PPI, positive pressure isolator; NPI, negative pressure isolator; SG-AI, 
supply grill auxiliary inflow; SG-PI, supply grill primary inflow; 
extractor grill (Osborne et al 1999)
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Appendix II
A Directa-valve with tube mount
B Vapouriser outlet
C Vapouriser
D Lid
E Directa-valve with tube mount
F Knob on top of directa-valve
G Fluovalve mask unit
H Induction chamber
I Tube mount and flow control
J Mask
K Fluosobe
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Appendix III 
Processing tissue to paraffin wax
Overnight schedule
Container Fluids Time Minutes
1 10% formalin 0
2 70% Alcohol 30
3 95% Alcohol 30
4 100% Alcohol 30
5 100% Alcohol 60
6 100% Alcohol 60
7 100% Alcohol 60
8 100% Alcohol/Xylene 30
9 Xylene 60
10 Xylene 120
11 Wax 150
12 Wax 240
Automated processing schedule using an enclosed 
processor (Tissue-TEK VIP machine, Miles Scientific). This was 
used to process the tissue removed from the mice (Anderson and 
Gordon 1996)
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